   
2020 -0074  
  08/16/[ADDRESS_243285] Of Serial 
Procalcitonin On Improving Antimicrobial Stewardship And On The 
Efficacy, Safety, And Tolerability Of Imipenem -Cilastatin -Relebactam 
Plus/Minus  Vancomycin Or Linezolid Versus Standard Of Care 
Antipseudomonal Beta -Lactams Plus /Minus  Vancomycin Or Linezolid 
As Empi[INVESTIGATOR_204059]  8 
Version Date  06/20/2022  
  
Protocol PI  [INVESTIGATOR_204060], M.D.  
Department  Infectious Diseases  
  
IND Sponsor  MD Anderson Cancer Center  
IND #  155191  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AN INVESTIGATOR INITIATED , PHASE I I SINGL E-CENTER , 
   
2020 -0074  
  08/16/[ADDRESS_243286] OF SERIAL PROCALCITONIN ON 
IMPROVING ANTIMICROBIAL STEWARDSHIP AND ON THE 
EFFICACY , SAFETY , AND TOLERABILITY OF IMIPENEM -
CILASTATIN -RELEBACTAM PLUS /MINUS  VANCOMYCIN  OR 
LINEZOLID VERSUS STANDARD OF CARE ANTIPSEUDOMONAL 
BETA -LAC TAMS PLUS /MINUS  VANCOMYCIN  OR LINEZOLID  AS 
EMPI[INVESTIGATOR_204061] W ITH 
CANCER  
 
   
2020 -0074  
  08/16/2023  
3 
   
 TABLE OF CONTENTS  
1.0 TABLE  2–1. SCHEDULE  OF ASSESSMENTS  AND  PROCEDURES  ........................ [ADDRESS_243287] imipenem non -susceptible and b -lactamase 
(ESBL, K PC, and serine carbapenemase) producing Enterobacteriaceae (2 - to 128 -fold 
MIC reductions) and against P. aeruginosa (eightfold MIC reduction). Clinical trials 
completed to date are summarized in Table (12 ), including two imipenem –relebactam 
phase II clin ical trials for the treatment of cIAI and cUTI/AP ([STUDY_ID_REMOVED] and 
[STUDY_ID_REMOVED]).  ................................ ................................ ................................ .................. 19 
7.2.1  Summary of Efficacy In Completed Clinical Studies  ................................ .......... 19 
7.3    Summary of Safety  ................................ ................................ .............................. 20 
7.4  In vitro Activity of Imipenem/relebactam and Comparator Agents  ................... 21 
8.0 STUDY OBJECTIVES  ................................ ................................ ................................ ....22 
9.0 INVESTIGATIONAL PLAN  ..........................  ERROR! BOOKMARK NOT DEFINED.  
9.1 Overall Study Design and Plan: Description  ................................ ..................... 22 
   
2020 -0074  
  08/16/2023  
4 
   
 9.2 This Section Intentionally Omitted  ................................ ................................ .....25 
9.3 Selection of Study Population  ................................ ................................ ............. 25 
9.3.1  Inclusion Criteria  ................................ ................................ ............................... 25 
9.3.2  Exclusion Criteria ................................ ................................ ............................... 26 
9.3.3  Removal of Patients  from Therapy or Study Assessment  ................................ ....27 
[IP_ADDRESS]  Premature Discontinuation from Inpatient IV Study Drug Due To Safety  ......... 27 
[IP_ADDRESS]  Premature Discontinuation from Inpatient IV Study Drug Due To Insufficient 
Therapeutic Effect  ................................ ................................ ................................ ............... 28 
[IP_ADDRESS]  Premature Discontinuation from Oral or IV Therapy  ................................ ........ 28 
[IP_ADDRESS]  Withdrawal  from Study  ................................ ................................ ....................... 28 
9.3.4  Patient Replacement Procedures  ................................ ................................ ........ 29 
9.4.1  TREATMENTS  ................................ ................................ ................................ ............... 29 
9.4.1  Treatment Group  ................................ ................................ ................................ 29 
[IP_ADDRESS]  Standard of Care Treatment Group  ................................ ................................ ....30 
[IP_ADDRESS]  Other Additional Antibacterial Therapy ................................ ............................. 31 
[IP_ADDRESS]  Optional Oral or IV Therapy Switch  ................................ ................................ ..33 
[IP_ADDRESS].1  Criteria for Switching to  Oral or IV Therapy  ................................ .................. 33 
[IP_ADDRESS].2  Oral and IV  Switch Therapy Options  ................................ ................................ 34 
[IP_ADDRESS]  Duration of Treatment  ................................ ................................ ........................ 36 
9.4.2 Identity of Investigational Products  ................................ ................................ ...36 
9.4.3  Method of Assigning Patients to Treatment Groups  ................................ .......... 38 
9.4.4  Selection of Dosages in the Study  ................................ ................................ .......38 
9.4.5  Selection and Timing of Dose for Each Patient  ................................ ................. 38 
[IP_ADDRESS]  Dose Adjustments for Imipenem -Cilastatin -Relebactam  ................................ ....39 
   
2020 -0074  
  08/16/2023  
5 
   
 [IP_ADDRESS]  Dose Adjustments - Other Investigational Products  ................................ .......... 40 
9.4.6  Blinding ................................ ................................ ................................ .............. 40 
9.4.7  Unblinding  ................................ ................................ ................................ .......... 40 
9.4.8  Prior and Concomitant Therapy ................................ ................................ ......... 40 
9.4.9  Monitoring Treatment Compliance  ................................ ................................ ....40 
9.5 EFFICACY AND SAFETY VARIABLES  ................................ ................................ .....40 
9.5.1  Primary and Secondary Efficacy Assessments  ................................ ................... 41 
[IP_ADDRESS]  Microbiological Assessments  ................................ ................................ ............. 41 
[IP_ADDRESS]  Clinical Outcome of The Infection  ................................ ................................ ......42 
9.5.2  Safety Assessments  ................................ ................................ .............................. 42 
[IP_ADDRESS]  Adverse Events  ................................ ................................ ................................ ....43 
[IP_ADDRESS]  Causality Assessment  ................................ ................................ .......................... 44 
[IP_ADDRESS] Serious Adverse Events (SAE) Reporting  ................................ ........................... 45 
[IP_ADDRESS]  Clinical Laboratory Determinations  ................................ ................................ ..48 
[IP_ADDRESS]  Vital Signs, Body Weight, and Height  ................................ ................................ 48 
[IP_ADDRESS]  Chest Radiography  ................................ ................................ ............................. 49 
[IP_ADDRESS]  Physical Examination  ................................ ................................ ......................... 49 
9.5.3  Schedule of Assessments  ................................ ................................ ..................... 49 
[IP_ADDRESS]  Baseline  ................................ ................................ ................................ .............. 49 
[IP_ADDRESS]  Study Da ys 1 To ≤ 14  ................................ ................................ .......................... 51 
[IP_ADDRESS]  End of Inpatient  Intravenous Therapy  ................................ ................................ 52 
[IP_ADDRESS]  Test-of-Cure (Toc)  ................................ ................................ .............................. 52 
[IP_ADDRESS]  Late Follow -Up................................ ................................ ................................ ...[ADDRESS_243288] Infection Symptoms, Including Recurring Or Worsening Symptoms Indicative of 
   
2020 -0074  
  08/16/2023  
6 
   
 Clinical Failure  ................................ ................................ ................................ .................. 53 
9.6 DATA  QUALITY  ASSURAN CE ................................ ................................ .................... 55 
9.6.1  Data Recording, Documentation and Monitoring  ................................ .............. 55 
9.6.2  Data Recording and Documentation  ................................ ................................ ..55 
9.7 STATI STICAL METHODS AND DETERMINATION OF SAMPLE SIZE  ............ 55 
9.7.1  Analysis Sets  ................................ ................................ ................................ .......55 
[IP_ADDRESS]  Screened Analysis Set  ................................ ................................ ......................... 57 
[IP_ADDRESS] Intent -To-Treat Analysis Set  ................................ ................................ ............... 57 
[IP_ADDRESS]  Safety Analysis Set  ................................ ................................ .............................. 57 
[IP_ADDRESS]  Modified Intent -To-Treat Analysis Set  ................................ ............................... 57 
[IP_ADDRESS]  Microbiological Modified Intent -To-Treat Analysis Set  ................................ ....57 
[IP_ADDRESS]  Clinically Evaluable Analysis Set  ................................ ................................ .......57 
[IP_ADDRESS]  Microbiologically Evaluable Analysis Set  ................................ .......................... 58 
9.7.2  Patient Disposition  ................................ ................................ ............................. 58 
9.7.3  Demographics and Other Baseline Characteristics  ................................ ........... 58 
9.7.4  Extent of Exposure and Treatment Compliance  ................................ ................. 59 
[IP_ADDRESS]  Extent of Exposure  ................................ ................................ .............................. 59 
[IP_ADDRESS]  Measurement of Treatment Compliance  ................................ ............................. 59 
9.7.5  Efficacy Analyses  ................................ ................................ ................................ 60 
[IP_ADDRESS]  Primary Efficacy Parameter  ................................ ................................ ............... 60 
[IP_ADDRESS]  Secondary Efficacy Parameters ................................ ................................ .......... 60 
[IP_ADDRESS]  Clinical Outcome Definitions  ................................ ................................ ............. 61 
[IP_ADDRESS]  Microbiological Response Definitions  ................................ ............................... 63 
[IP_ADDRESS]  Emergent Infections  ................................ ................................ ............................ 64 
   
2020 -0074  
  08/16/2023  
7 
   
 9.7.6  Safety Analyses  ................................ ................................ ................................ ...64 
[IP_ADDRESS]  Adverse Events  ................................ ................................ ................................ ....65 
[IP_ADDRESS]  Clinical Laboratory Parameters  ................................ ................................ ........ 65 
[IP_ADDRESS]  Vital Signs  ................................ ................................ ................................ ........... 66 
[IP_ADDRESS]  Chest Radiography  ................................ ................................ ............................. 66 
[IP_ADDRESS]  Stoppi[INVESTIGATOR_10020]  ................................ ................................ ................................ ......[ADDRESS_243289] OF THE STUDY OR PLANNED ANALYSES  ....69 
9.9 PROTOCOL DEVIATIONS  ................................ ................................ ........................... 69 
10.0  STUDY  FUNDER SHIP  ................................ ................................ ................................ ....69 
10.1  STUDY TERMINATION  ................................ ................................ ................................ 69 
10.2  REPORTING AND PUBLICATION  ................................ ................................ ............. 69 
11.0 INVESTIGATOR OBLIGATIONS  ................................ ................................ ................ 69 
11.1  DOCUMENTATION  ................................ ................................ ................................ .......69 
11.2  USE OF INVESTIGATIO NAL MATERIALS  ................................ ............................. 70 
11.3  CASE REPORT FORMS  ................................ ................................ ................................ 70 
11.4  RETENTION AND REVIEW OF RECORDS  ................................ .............................. 70 
11.5  PATIEN T CONFIDENTIALITY  ................................ ................................ ................... 70 
12.0  APPENDICES  ................................ ................................ ................................ ................... 70 
APPENDI X I. ELEMENTS OF INFORMED  CONSENT  ................................ ................... 70 
APPENDI X II. MD AND ERSON NEUTROPENIC  FEVER INPATIENT ADUL T 
   
2020 -0074  
  08/16/2023  
8 
   
 TREATMEN T GUID ELINES  ................................ ................................ ................................ ....73 
APPENDI X III. MD AND ERSO N PNEUMON IA IN ADULT PATIENTS WITH 
CANCE R TREATMEN T GUIDELINES  ................................ ................................ .................. 82 
APPENDI X IV. POTENTIAL DRU G-INDUCED LIVER INJURY/HY’S LAW  .............. 92 
APPENDIX V.  INVESTIGATORS BROCHURE  . ERROR! BOOKMARK NOT DEFINED.  
PHL  ................................ ................................ ................................ ................................ ............... 93 
FOLLOW -UP AND  REPORTING  ................................ ................................ ............................ 93 
REFERENCE  ................................ ................................ ................................ ............................... 94 
13.0  LITERATURE CITED  ................................ ................................ ................................ ....96 
    
2020 -0074  
  08/16/2023  
9 
 1.0 TABLE  2–1. SCHEDULE  OF ASSESSMENTS  AND  
PROCEDURES  
  
 
Assessment  or Procedure   
Base linea Treatment  Follo w-up 
Study  Days  1 to ≤ 
14b  
EOIVc  
TOCd  
LFUe 
Informed  consen tf X     
Inclusion/exclusion  criteria  X     
Medical  and surgical  histor yg X     
Height  and weigh th X     
Chest  radiograph yi X  If clinically  indicated  
Physical examinat ion X Xj X X Xk 
Vital  signsl X X X X Xk 
Prior/concomitant  medication sm X X X X X 
AEs and SAEs  X X X X X 
Clinical  outcome    X X X 
 
Laboratory  testsn  
X If clinically  
indicate do  
Xp   
  
  
Absolute  neutrophil  count  X Xq X   
Urine or Serum  pregnancy  testr X     
 
CrCl  calculatio ns  
X  
Xj if clinically  
indicated    
  
  
Blood  culture  X XT Xu as clinically  indicated  
Urine culture/urine analysis (when clinically 
needed)  X as 
clinically 
indicated   as clinically  indicated  
Other samples for culture from possible suspected 
infected site if clinically indicated t if clinically  indicated  
Randomization  X     
Study  drug administration   Xv X   
a Perform baseline assessments within [ADDRESS_243290] day of inpatient IV study drug administration;  subsequent  study  days are 
consecutive calendar days.  Baseline and Study day 1 assessment could be combined if they occur on the 
same calendar day. . On  
Study Days 1 to ≤  14, study drug administration applies to all patient s, and assessment s are to be performe d 
for patients on inpatien t IV study drug only. T reatment duration is 2 to 14 days with a minimum of 2 days 
(ie, 48 hours and  a minimum  of 8 doses  for Imipenem -Cilastatin -Relebactam  and SOC therapi[INVESTIGATOR_014], except 
pi[INVESTIGATOR_049]/tazobactam, which is a minimum of 8 doses) of inpatient IV study drug.  
c Perform EOIV assessments in person within [ADDRESS_243291] 48 hours of  
IV gram negative antimicrobial coverage and procalcitonin () downward drops by 30% from baseline or is 
below than 0.25   (Section [IP_ADDRESS] ). 
d Perform TOC assessments in person between Study Days [ADDRESS_243292] ongoing study 
drug related AEs or SAEs at TOC, or did not develo p any study  drug related AEs or SAE s since TOC . If 
symptom s consistent with clinical failure  or new study drug related AEs or SAEs are noted, or at the 
    
2020 -0074  
  08/16/[ADDRESS_243293] known or stated height and w eight.  
i CXR (eg, portable anteroposterior film) or chest  CT for patient s with respi[INVESTIGATOR_13521] y signs or symptoms.  
j  Every [ADDRESS_243294] dose, while the patient is hospi[INVESTIGATOR_204062], 
whereby [CONTACT_204096].   The patient could receive unscheduled assessment, if 
deemed necessary at the discretion of the inve stigator. The investigator can rely on the physical exam 
performed by a professionally trained physician or health professional licensed to perform physical 
examinations.  
k Do not perform if LFU is conducted via telephone.  
l Blood  pressure  (systolic  and diasto lic) and pulse  rate, respi[INVESTIGATOR_2842], oxygen  saturation  (if 
applicable),  and highest  daily  temperature.  
m Record medications, including antimicrobials  (ie, antibacterials, antivirals, antifungals, antiparasitics ), over -
the- counter  medications  (eg, vitamins , herbal  medications),  and parenteral  nutrition  taken  or received  within  
[ADDRESS_243295] dose of inpatient  IV study drug throug h LFU.  
n Refer to Section [IP_ADDRESS] for a detailed list of laboratory tests. Results from unscheduled laboratory tests will not 
be collected, unless associated with an SAE or AE leading to discontinuation of IV study drug. Any abnormal  
laboratory test possibly attributable to IV study drugs will be repeated at appropriate intervals until it returns to 
normal.  
o Perform on Study Day 7 if  still on IV study drug.  
p At EOIV, perform laboratory tests if laboratory tests for EOIV is obtained ≥ [ADDRESS_243296] 
dose (if applicable).  
q Record absolute neutrophil count a minimum of 3 times per week while on study therapy (IV or oral). For  
patients who switch to oral or IV therapy, at the discretion of the Investigator, record absolute neutrophil 
count as clinically indicated between EOIV and TOC.  
r Women of childbearing potential only (including those who are fewer than 2 years postmenopausal); ensure test is 
negative before randomization within [ADDRESS_243297] 1-2 blood cultures 
from separate venipuncture sites , preferably . Obtain blood samples for culture every other day until 
temperature is  ≤ 100.4°F (38.0°C)  and cultures are negativ e. 
u If baseline cultures were positive, r epeat blood cul tures at EOIV if clinically indicated  to determin e 
microbiologica l response.  
v Administe r study drug per Section  9.4.1. 
 
AE = adverse event; CrCl  = creatinine clearance; CT  = computed tomography; CVC =  central venous catheter;  
CXR =  chest  radiograph y; EOIV =  End of Inpatient  Intravenou s Thera py; IV = intravenous; LFU = Late 
Follo w-up; SAE = serious adverse event; TOC =  Test-of-Cure.  
    
2020 -0074  
  08/16/[ADDRESS_243298]  OF IN-TEXT  TABLES    
Table  2–1. Schedule  of Assess ments and Procedures  ..................................  13 
Table  9.4.1 .3–1. Investigational  Products  ....................................................   32 
Table  9.4.5 .1–1. Imipenem -Cilastatin -Relebactam   Dosage  Adjust ments for   
Renal Impairment ……………………………………………………… ..... 36 
Table  9.7.5 .3–1. Clinical  Outco me Definition s............................................   55 
Table  9.7.5 .4–1. Micro biological  Response  Definitions  ..............................   58 
Table  9.7.5 .5–1. Emergent  Infection s...........................................................   58 
    
2020 -0074  
  08/16/[ADDRESS_243299]  OF IN-TEXT  FIGURES  
Figure  9.1–1. Study  Design  ........................................................   30 
Figure  9.7.1 –1. Analysis  Sets for Study   .................................  62 
    
2020 -0074  
  08/16/[ADDRESS_243300] O F ABBREVIATIO NS  
%fT > CT percent  of time that free drug concentrations  are above  a threshold  
concentration  over a dose interval  
 
%fT > MIC  percent  of time that free drug concentrations  are above  the 
minimum  inhibitory  concentration  over a dose interval  
 
AE adverse  event  
 
ALP alkaline  phosphatase  
 
ALT alanine  aminotransferase  
 
ANC  absolute  neutrophil  count  
 
AmpC  Ambler  Class  C 
 
AST aspartate  aminotransferase  
 
CE clinically  evaluable  
 
CFR  Code  of Federal  Regulations  
 
cIAI complicated  intra-abdominal  infection  
 
CrCl creatinine  clearance  
 
CT computed  tomography  
 
cUTI complicated  urinary  tract infection  
 
CXR chest x-ray 
 
eCRF  electronic  case report  form  
 
EDC  electronic  data capture  
 
EOIV  End of Inpatient  Intravenous  Therapy  
 
ESBL  extende d-spectrum  β-lactamase  
    
2020 -0074  
  08/16/[ADDRESS_243301] of 1996  
 
ICF informed  consent  form  
 
ICH International  Conference  on Harmonisation  
 
IMI Imipenem/cilastatin  
 
IND Investigational  New  Drug  
 
IRB Institutional  Review  Board  
 
ITT intent-to-treat 
 
IV intravenou s, intravenously  
 
LAR  legally  authorized  representative  
 
LFU Late Follo w-up 
 
MDR  multidrug  resistant  
 
ME microbiologically  evaluable  
 
MedDRA  Medical  Dictionary  for Regulatory  Activities  
 
MITT  modified  intent-to-treat 
 
mMITT  microbiological  modified  intent-to-treat 
 
MTZ metronidazole  
 
PCS potentially  clinically  significant  
 
PHL potential  Hy’s  Law 
 
PID patient  identification  
 
PK pharmacokinetic  
 
PK/P D pharmacokinetic/pharmacodynamic  
 
q8h every  8 hours  
    
2020 -0074  
  08/16/[ADDRESS_243302] upper  limit  of normal  
    
2020 -0074  
  08/16/[ADDRESS_243303] (IRB) before the start of the study will be the 
responsibility of the Investigator. A copy of the approval letter will be supplied to  
[COMPANY_006] , Inc. along with a roster of IRB members or the US Department of Health and Human 
Services general assurance number. During the course of the study, the Investigato r will provide 
timely and accurate reports to the IRB on the progress of the study, at intervals not exceeding 1 
year (or as appropriate), and will notify the IRB of serious adverse events (SAEs) or other 
significant safety findings. The study protocol, in formed consent form (ICF), information sheet 
advertisements, and amendments (if any) will be approved by [CONTACT_204097], Title 21, Part 56.  
 
 
5.[ADDRESS_243304] their 
origins in the Declaration of Helsinki.  
 
This clinical study will comply with ICH Guidance on General Considerations for Clinical Trials 
(ICH -E8; 62 FR [ZIP_CODE], 17 Dec 1997) and Good Clinical Practice  (ICH -E6; 62 FR [ZIP_CODE] , 09 
May 1997), as well as Part 312 of the CFR.  
 
 
5.3 Patient Information a nd Informed Consent  
 
Patients, after being given an explanation of the study, will give voluntary and written informed 
consent and HIPAA authorization (in compliance with 21 CFR, Parts 50 and  312) before 
participating in any study -related procedures.  
 
Each patient (or his or her legally authorized representative) will read, assent to an understanding 
of, and sign an instrument of ICF after having had an opportunity to discuss it with the study 
staff before signing; each patient will be made aware that he or she may withdraw from the study 
at any time.  
 
The informed consent statement contains all the elements of informed consent listed in Appendix 
I of this protocol. Signed copi[INVESTIGATOR_204063], and both documents will 
be placed in the Investigator’s study files.  
    
2020 -0074  
  08/16/2023  
17 
 6.0 INVESTIGATORS AND STUDY ADMINISTRATIVE 
STRUCTURE  
 
This study will be performed at 1 study center in  the [LOCATION_002] (MD Anderson Cancer 
Center, Houston, [LOCATION_007]).  
 
The Investigator is responsible for ensuring that the study is conducted according to the signed 
Investigator statement, the investigational plan, GCP guidelines, and applicable regulations; for 
protecting the rights, safety, and welfare of patients under the Investigator’s care; and for the 
control of investigational products under investigation. An Investigator shall obtain the informed 
consent of each human patient prior to the patient enro lling in the study and/or prior to 
participating in any study -related activity.  
 
The Investigator must meet his or her obligations to the patients, ethics committee, Funder , and 
regulatory authorities by [CONTACT_204098]’s con duct and the study 
staff. It is the responsibility of the Investigator to ensure that any and all delegated duties be 
assigned to qualified staff by [CONTACT_8640], experience, and licensure (in accordance with local 
regulations) and that the Investigator overs ight is documented and assessment of their 
capabilities and performance consistent with the study investigational plan. The Investigator will 
be responsible for the management of the study, including maintaining the study file and the 
patient records, corr esponding with the IRB, and completing the electronic case report forms 
(eCRFs).   
    
2020 -0074  
  08/16/2023  
18 
  
7.0 INTRODUCTION  
 
7.1 Background and Study Rationale  
 
 
Infections caused by [CONTACT_71512] -resistant Gram -negative pathogens, ESBL -producing 
Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp., are difficult to treat and 
associated with high mortality  (1-5).  Carbapenems fulfil a critical role in the treatment of serious 
bacterial  infections due to these pathogens, both as empi[INVESTIGATOR_204064]  
(6-10). The increasing prevalence of carbapenem -resistant bacterial pathogens is therefore a 
major global health threat, with the US CDC considering carbapenemresistant 
Enterobacteriaceae, one of only three bacterial threats at the highest hazard level  (11-13). The 
most common carbapenem resistance mechanism is the production of carbapenemases, which are 
b-lactamase enzymes able to hydrolyse carbapenem -class antibacterials  (14).  
 Resistance can also be mediated by [CONTACT_39785] b -lactamases combined with additional mechanisms, 
such as porin loss and/or efflux pump expression (7, 15 -18). 
 
Among various strategies, the most successful in increasing the life span of -lactam antibiotics 
has been their combination with new agents capable of inhibiting a broad spectrum of –
lactamases  (10). Relebactam  is a -lactamase inh ibitor that inhibits two different classes of -
lactamases: class A -lactamases (serine -containing -lactamases, such as the Klebsiella 
pneumoniae carbapenemase) and class C -lactamases (such as AmpC cephalosporinases) (7) 
Relebactam is suitable for combination with the well -established carbapenem 
imipenem/cilastatin (IMI): inhibiting AmpC frequently restores Pseudomonas aeruginosa 
susceptibility to imipenem bu t not other carbapenems, neither agent is subject to efflux in P. 
aeruginosa, and their pharmacokinetic/pharmacodynamic profiles complement each other (9, 10) .  
Combini ng relebactam with IMI (IMI/REL) can restore IMI activity against many imipenem -
nonsusceptible gram -negative pathogens, including extended -spectrum β -lactamase (ESBL) -, 
AmpC -, and KPC -producing Enterobacteriaceae (19, 20) . Two phase 2 trials found IMI/RE L 
safe and no less effective than IMI for complicated intraabdominal and urinary tract infections 
(14, 21 -23). In addition the Pi[INVESTIGATOR_204065] -IMI 2 Phase 3 Study of [COMPANY_006]’s RECARBRIO™ 
(imipenem, cilastatin, and relebactam) in Hospi[INVESTIGATOR_307] -Acquired and Ventilator -Associated Bacterial 
Pneumonia (HABP/VABP). This trial met Primary Endpoint. For both t he primary and 
secondary efficacy end points, IMI/REL was non -inferior (p <0.001) to PIP/TAZ. The rates of 
adverse events (AEs) in the safety population (IMI/REL 226/266 [85.0%] vs PIP/TAZ 233/269 
[86.6%]), as well as therapy discontinuations due to both o verall AEs and specifically due to 
drug-related AEs, were similar across both treatment arms. Diarrhea, increase alanine 
aminotransferase, and increased aspartate aminotransferase were the most common AEs (6/266 
[2.3%] each). Therefore IMI/REL is an effica cious and well -tolerated treatment option for 
HABP/VABP.   Pharmacokinetic/pharmacodynamic analyses (21, 24)  confirmed  500 mg IMI 
plus 250 mg REL as the optimum IMI/ REL dose for further clinical evaluation . 
 
Therefore, the novel β -lactamase inhibitors relebactam are  being developed to address the need 
for agents with activity against carbapenem -resistant Gram -negative , such as Imipenem –
Relebactam.  This antibiotic ( Imipenem -Cilastatin -Relebactam ) will be compared to standard of 
    
2020 -0074  
  08/16/2023  
19 
 care other anti -pseudomonal beta -lactams ( e.g.Cefepi[INVESTIGATOR_048], Meropenem or 
Pi[INVESTIGATOR_049]/Tazobactam) in patients with neutropenia and fever. This study us es Procalcitonin 
(PCT) as a theragnostic biomarker that promotes antimicrobial stewardship and the need to 
switch and streamline these broad spectrum IV antibiotics by [ADDRESS_243305] has been studied by [CONTACT_204099] i n the setting of neutropenic fever and has 
been shown to be a useful tool for assessing the response to antimicrobial therapy particularly 
between 48 and 72 hours  (25-31). Furthermore, it has been high ly studied in high risk patients 
such as critically ill patients and patients with lower respi[INVESTIGATOR_204066] a useful tool for antimicrobial stewardship and for streamlining antimicrobial therapy (to 
either oral regimen or simplified IV regimen) or discontinuing antimicrobial therapy  (32-35). 
Hence, it is being used in this current s tudy for antimicrobial stewardship to prevent unnecessary 
prolonged use of broad spectrum antimicrobial therapy.  
 
 
7.[ADDRESS_243306] imipenem non -susceptible and b -lactamase (ESBL, KPC, and 
serine carbapenemase) producing Enterobacteriaceae (2 - to 128 -fold MIC reductions) and 
against P. aeruginosa (eightfold MIC reduction). Clinical trials completed to date are 
summarized in Table ( 12 ), including two imipenem –relebactam phase II clinical trials for the 
treatment of cIAI and cUTI/AP ([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]).  
 
7.2.1  Summary of Effica cy In Completed Clinical Studies  
The efficacy, tolerability, and safety of imipenem –relebactam has been studied for the treatment 
of cIAI in a global, double -blind, randomized, phase II, non -inferiority trial ([STUDY_ID_REMOVED]) 
(Table II) (21). Imipenem/ cilastatinrele bactam (500/500/250 mg and 500/500/125 mg) were 
compared to imipenem/cilastatin alone (500/500 mg), administered IV (t’ 30 min) q6 h for 4 –14 
days. The dose of imipenem was adjusted for renal insufficiency and/or low body weight 
according to the approved l abel at the time of the trial , and the dose of relebactam was adjusted 
proportionally. In this study, 351 patients were BLOCK randomized (1:1:1) . Clinical response in 
the ME population at EFU and LFU was similar to the response seen at DCIV, and was simil ar 
across all three treatment groups (Table II). 
 
The efficacy, tolerability, and safety of imipenem –relebactam has been studied for the 
treatment of cUTI and AP in a global, double -blind, randomized, phase II, non -inferiority trial) 
(14). Imipenem/cilastatin -relebactam (500/500/250  mg and 500/500/125  mg) was  compared to 
imipenem/cilas tatin alone (500/500  mg), administered IV ( t’ 30 min) q6  h with optional oral 
step-down to ciprofloxacin after at least 4  days of IV therapy. The total treatment duration was 
a maximum of 14  days. The dose of imipenem was adjusted for renal insufficiency a nd/or low 
body weight according to the approved label  at the time of the trial , and the dose of relebactam 
was adjusted proportionally. In this study, 302 patients were block randomized 1:1:1.  
The primary outcome was a favorable microbiological response i n the ME population at DCIV. 
Microbiological response was determined based on urine culture results on follow -up relative 
to the pathogen(s) isolated at baseline. The ME population was defined as subjects with an 
    
2020 -0074  
  08/16/[ADDRESS_243307] one Gram -negative 
enteric and/or anaerobic pathogen at a sufficient quantity, and no significant protocol 
deviations, who received at least 4  days of IV study therapy.  
The ME population at DCIV included 77.2% of randomized patie nts. A non -inferiority margin 
was set at  ≥ 15% for the lower bound of the 95% CI, with 87% power to determine non -
inferiority of imipenem –relebactam compared to imipenem alone. Microbiological response in 
the ME population at DCIV (primary outcome) for the  relebactam arm 250  mg was 95.5 versus 
98.7% for imipenem alone, a difference of −  3.1% (95% CI −  11.3 to 3.2), while response for 
the relebactam 125  mg arm was 98.6 versus 98.7% for imipenem alone (95% CI −  6.4 to 5.9). 
Therefore, both regimens were non -inferior to imipenem alone for the primary outcome.  
 
 
 
 
7.3    Summary of Safety  
 
 
In a Phase II study comparing the treatment of cUTI and AP, drug -related adverse events 
occurred in 10.1, 9.1, and 9% of patients for treatment with imipenem/cilastatin -relebactam 
500/500/250  mg, imipenem/cilastatin -relebactam 500/500/125  mg, and imipenem/cilastatin 
500/500  mg, respectively  (14). No deaths occurred; however, serious treatment -emergent 
adverse events were reported in 3.0, 1.0, and 3.0%, respectively. The most common treatment -
emergent adverse events included nausea, headache and diarrhea, which were relatively similar 
in all three treatment groups (range of 2.0 –7.1%). Treatment -related adverse events leading to 
discontinuation occur red in four patients, 2 (2%), 1 (1%), and 1 (1%) in the three treatment 
groups, respectively, due to diarrhea, rash, nausea, and diarrhea. One patient in the relebactam 
[ADDRESS_243308] elevations  ≥ 5× ULN, determined to be drug related.
    
2020 -0074  
  08/16/2023  
21 
 7.4  In vitro Activity of Imipenem/relebactam and 
Comparator Agents  

 2020 -0074  
 06/20/2022  
22  
  
8.0 STUDY OBJECTIVES  
 
Primary:  
• To evaluate the efficacy  of imipenem –cilastatin -relebactam plus/minus  vancom ycin, 
daptomycin or linezolid vs  standar d of care (SOC) plus /minus  vancom ycin, daptomycin  or 
linezolid as empi[INVESTIGATOR_204067]  (EOIV ) in the Modified  Inten t-to-
Treat (MITT) Anal ysis Set . 
 
• To evaluate the safe ty and tolerability  of imipenem -cilastatin –relebactam  plus/minus  
vanco mycin, daptomycin, or linezolid compared with SOC plus /minus  vanco mycin, daptomycin  
or linezolid as empi[INVESTIGATOR_204068] . 
 
 
 
Secondary : 
• To evaluate the efficacy  of imipenem -cilastatin –relebactam plus/minus  vancom ycin, 
daptomycin  or linezolid  compared  with SOC plus /minus  vancom ycin, daptomycin  or linezolid 
as empi[INVESTIGATOR_204069] r with respect to the following:  
 
○ Favorable clinical response  at EOIV in the mMITT and Clinically  Evaluable (CE) analysis sets . 
 
○ Favorable clinical response  at TOC (ie, 21 to 28 da ys after start of  IV therap y) and LFU (ie, 35  
to 42 days after start of IV therap y) in the MITT Anal ysis Set. 
 
○ Favorable clinical response  by [CONTACT_204100] -negative pathogen at EOIV , TOC, and LFU  in the 
mMITT and CE anal ysis sets . 
 
○ Favorabl e microbiologica l respons e by [CONTACT_204101] -negative pathoge n at EOIV, 
TOC, and LFU  in the mM ITT and ME  analysis sets . 
 
○ Infection -related mortality  rate at TOC and LFU  in the MITT and mMITT ana lysis sets . 
 
○ 30-day all-cause mortality  rate in the MITT and mM ITT ana lysis sets . 
 
• To evaluate the role of PCT in promoting antimicrobial stewardship resulting in the switch of 
most patients from the broad spectrum agents (Imipenem /Cilastatin /Relebactam & SOC) to a 
more simplified IV or oral  antibiotic therapy within  48-72 hours.  
 
9.0 Investigational Plan:  
9.1 Overall Study De sign and Plan: Description  
 
This clinical study  will be a singl e-center, randomized, open -label , parallel -group study 
comparin g imipenem -cilastatin –relebactam plus/minus  vanco mycin, daptomycin  or linezoli d 
with SOC plus /minus  vanco mycin, daptomycin  or linezoli d as empi[INVESTIGATOR_204070] e 
neutropeni c adult s with cance r. The total duration  of study  therapy  will be  2 to 14 days; a 
minimum of 2 days (ie, 48 hours of IV antimicrobial gram negative coverage  is required ; 
 2020 -0074  
 06/20/2022  
23  
 duration of treatment is discussed in Section  [IP_ADDRESS]. IV study drug is define d as the IV 
treatment for Gra m-negativ e coverag e (or SOC) that the patient is receiving for the 
neutropenic febrile epi[INVESTIGATOR_1865] ). A switc h to open -label oral or IV thera py may be allowe d after at 
least 48 hours IV gram negative antimicrobial coverage  per Section 9.4.1.  Doses of SOC 
antibiotics given before signing informed consent will be counted.  
Gram positive antimicrobial coverage (ie vancomycin, linezolid or daptomycin) is optional and 
can be given if clinically indicated  at the discretion of the primary team or emergency center 
physician . Gram positive antimicrobial coverage can also be switched  at any time during the 
study.  
 
 
 
  
 2020 -0074  
 06/20/2022  
24  
 
IV SOC plus /minus  
Vancomycin, 
Daptomycin or 
Linezolid  IV SOC plus /minus  Vancomycin, Daptomycin 
or linezolid  
 
 
Figure  9.1–1. Study  Design  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 IV Imipenem relebactam  
Plus/minus  Vancomycin, 
Daptomycin or Linezolid  IV Imipenem relebactam  plus/minus  Vancomycin , 
Daptomycin  or Linezolid  
 2020 -0074  
 06/20/[ADDRESS_243309] meet the followin g criteria: 
 
1. Has provided written informed consent, and has the willingness and ability to comp ly with all 
study  procedures  
 
2. Male or female , ≥ [ADDRESS_243310]  undergone hematopoietic  
stem cell transplantatio n. Neutropenic  fever  is defined  as the presence of neutropeni a defined by: 
1) Absolute neutrophil count (ANC)  < 500 cells/mm3 or has an ANC  that is expected  to decrease  
to < 500 cells/mm3 withi n 48 hours of trial entry  and fever defined as: 2)  Single oral temperature 
measurement of >  100.4°F (38.0°C)   
 
4. Requires hospi[INVESTIGATOR_204071] 
 
5. If female:  
 
○ Not breastfeeding  
 
○ Agrees to not attempt to become pregnant during the study  
 
 
 2020 -0074  
 06/20/[ADDRESS_243311] within 5 days  
 
○ If of childbearing potential (including being < 2  years postmenopausal) , is willing to practice 
sexual abstinence or use an effective dual form of contraception with her partne r (eg, 2 barrier 
methods, barrier method plus hormonal method) during treatment and up [ADDRESS_243312] treatment.  
 
 
9.3.2  Exclusion Criteria  
 
Patients who meet a ny of the following criteria will not be eligible to participate in the stu dy: 
 
1. History  of any hypersensitivity  or allergic reaction to any  carbapenem  
 
2. Fever suspected to be caused by  a noninfectious cause (eg, fever relate d to drug or blood product 
administratio n) 
 
3. Confirme d funga l infection (eg, Pneumocystis  jirovecii  etiology  in patients with pneumoni a) that 
justifies addin g additional  empi[INVESTIGATOR_204072] l thera py (eg, antifungals)  
 
4. Confirmed  viral infection  that justifies  adding  additional  empi[INVESTIGATOR_204073] (eg, 
ganciclovir, foscarnet)  
 
5. Evidence of significant hepatic impairment (a ny of the  following):  
 
○ Known acute viral hepatitis  
 
Alanine aminotransferase (ALT) level  > 5 times the upper limit of normal (× ULN).  
Total bilirubin > 3 × ULN unless isolated h yperbilirubinemia is directly  related to the acute 
infectio n or due to know n Gilber t disease 
○ Manifestation s of end-stage liver disease, such as ascites or hepatic encep halopathy  
 
6. Known to be human immunodeficiency  virus positive  
 
7. Severe ly impaire d renal function , define d as creatinin e clearanc e (CrCl ) ≤ 30 mL/min estimated 
by [CONTACT_16424] -Gaul t formul a (Section [IP_ADDRESS] ) 
 
8. Expected requirement for hemodial ysis while on study therapy  
 
9. Receive d > 36 hours of IV antib acterial therapy  (with study drugs) within [ADDRESS_243313] or current history  of epil epsy or seizure disorder; exception: well-documented febrile  
seizure  of childhood  
 
11. Evidenc e of immediate ly life-threatenin g disease , progressive ly fatal diseas e, or life expectancy  
of 3 months or less (e g, moribund or with shock unresponsive to fluid replacemen t) 
 2020 -0074  
 06/20/2022  
27  
 12. Unable  or unwilling  to adhere  to the study-specified procedures and r estrictions  
 
13. Any condition that would make the patient, in the opi[INVESTIGATOR_689], unsuitabl e for the 
study (eg, woul d place a patien t at risk or compromis e the quality o f the data   
 
14. Participation in any other ongoing imipenem -cilastatin –relebactam  trial. 
 
15. Prior participation on this trial  
 
 
9.3.[ADDRESS_243314] less of circumstances, ceases participation in the stud y, before the completion of all study  
assessments (ie, before completing all protoco l-stipulated activities).  In addition, patient s can be 
premature ly discontinue d from the study  after careful consider ation for one of the reasons listed 
in Section [IP_ADDRESS].  
 
Follow -up of patients prematurely  discontinued from inpatient  IV study drug or oral or IV 
thera py or withdrawn  from  the study  will be conducted  as described  below.  
 
 
[IP_ADDRESS]  Premature Discontinuation f rom Inpatient I V Study 
Drug Due To Safety  
 
Reasons:  Possible reasons for premature discontinuation from study  drug administration  
due to safety include, but are not limited t o: 
 
Occurrence of a related, possibly or probab ly related AE that, in the opi[INVESTIGATOR_689] , 
warrant s the patient ’s permanent discontinuation from  IV study drug 
 
Known pregnancy  or breastfeeding during the study  therapy  administration period.  
 
The patien t meets criteria f or dru g-induced liver injury  per Appendix V, at the discretion of the 
Investigator  
 
Investigator determines that it is in the best interest of the patient to discontinue study drug, due 
to reasons other than an adverse event (AE)  
 
Assessments and Procedures:  A patien t who is premature ly discontinue d from inpatient  
IV study  drug (ie, before the anticipated full course of study  therapy  required for effectiv e 
treatmen t of febril e neutropenia ) for safety  reasons shoul d have EOIV assessments  conducted  
 2020 -0074  
 06/20/2022  
28  
 and undergo  safety assessment s at TOC and LFU.  
 
Clinical  Outcome  Assessment:  See Table 9.7.5. 3–1 
 
 
[IP_ADDRESS]  Premature Discontinuation from  Inpatient IV Study 
Drug Due To Insufficient Therapeutic Effect  
 
Reasons:  Possible reasons for discontinuation from study  drug due to insufficient therapeuti c 
effect include, but are not limited to:  
 
Clinical  worsening : A patient who shows signs of clinical worsening may  be premature ly 
discontinue d from inpatient IV study drug at any time. If the Investiga tor deem s the benefit -to-
risk ratio of inpatient  IV study drug continuance acceptable, administration  of at least 48 hours  is 
encouraged  before  discontinuation.  
 
Lack  of clinical  progress : For a patient who is stable, yet does not show signs of improvement , 
the Investigator is encouraged to continue  inpatient IV study drug  for at least 48 hours before 
such a patient is considered a clinical failur e and is premature ly discontinue d from IV study drug 
 
Assessments and Procedures:  A patien t who  is premature ly discontinued from  inpatient IV 
study  drug due to insufficient therapeutic effect  should have EOIV assessments conducte d and 
underg o safety assessment s at TOC and LFU . If a patien t is discontinued from inpatient IV study 
drug due to insufficient therapeutic ef fect and is switche d to an alternativ e IV antibiotic , that 
thera py shoul d be recorde d. 
 
Clinical  Outcome  Assessment:  See Table 9.7.5. 3–1. 
 
[IP_ADDRESS]  Premature Discontinuation from  Oral or IV Therapy  
 
A patien t who is premature ly discontinue d from oral or IV therapy  for any reason will not have 
protocol assessments conducte d until TOC (ie, there is no scheduled visit betwee n EOIV and 
TOC) . At an unscheduled  visit or at TOC,  whichever  occurs  first, recor d the date of and reason 
for discontinuation.  See Table [IP_ADDRESS] –1 for clinical outcome  definitions  at TOC. 
 
[IP_ADDRESS]     Withdrawal  from  Study  
 
Reasons:  Possible reasons for withdrawal from study  depend on the timing of the withdrawal, 
and include, but a re not limited to:  
 
Before administration of first dose of study  therap y: 
 
Screen failure (failure to meet inclusion/exclusion criteria)  
 
Withdrawal of consent  at any time during the study period.  
 
AE 
 
Protocol violation  
 2020 -0074  
 06/20/[ADDRESS_243315] of the  patient to withdraw from the 
study  protocol, due to reasons other than an AE  
 
An AE should not be a reason for withdrawal from study  after study  drug has been administered. 
The patient may  be discontinued from study  drug due to an AE, in which case they should be 
encouraged to stay  in the study  for follo w-up safe ty asses sments. 
 
Note: If death was due to an AE, then the AE is the  reaso n for discontinuin g study drug and death  
is the reason  for withdrawa l from stud y. If the death is due to lack of effi cacy, then lack of 
efficacy  is the reason for discontinuing study  drug, and death is the reason for withdrawa l from 
study. 
 
 
Assessment s and Procedures:  Patients may  withdraw from the stud y, or be withdrawn at the 
request of the Investigator or Funder . A patient who is withdrawn completely from the study  
during  inpatient  IV study drug or oral or IV thera py shoul d be encourage d to undergo , if 
possible, EOIV (if on  inpatient IV study drug) or TOC (if on ora l or IV therap y) assessments on 
the day  of withdrawal. Patients withdrawn from the study  need not undergo subsequent TOC 
efficacy  assessments (if on inpatient  IV study drug) or LFU (if on oral or IV thera py) 
assessments.  
 
Clinical  Outcome  Assessment:  A patient withdrawn from the study  who is not assessed as a 
clinical failure should be assessed as indeterminate at all subsequent outcome evaluation time 
points (Table [IP_ADDRESS] –1). 
 
9.3.[ADDRESS_243316] one dose of study drug will 
not be replaced.  Patients who withdraw consent prior to receiving any dose of study drug will be 
replaced by [CONTACT_204102].  
 
 
 
9.4.1  TREATMENTS  
 
Treatments Administered  
 
 9.4.1  Treatment Group  
 
As shown in Table [IP_ADDRESS] -1, patients randomized to the  Imipenem -Cilastatin -Relebactam  
 2020 -0074  
 06/20/2022  
30  
 treatment  group will receive:  
 
Imipenem -Relebatam: 500 mg Imipenem, 500 mg ci lastatin and  250 mg of Relebactam IV over 
30 min Q6 hours  
 
IV Imipenem /Cilastatin /Relebactam  (minimum of 8 doses)  
 
Gram positive antimicrobial coverage (ie vancomycin, linezolid or daptomycin) is optional and 
can be given if clinically indicated at the discretion of the primary team or emergency center 
physician. Gram positive antimicrobial coverage can also be switche d at any time during the 
study.  
Daptomycin could be given if there is no evidence of pneumonia.  
 
Patient may continue on the study drug up to 14 days if clinically indicated by [CONTACT_204103] [IP_ADDRESS]. Patients may be 
eligible to switch to outpatien t IV or oral thera py, as discussed in  
Section [IP_ADDRESS].  
 
 
 
[IP_ADDRESS] Standard of Care Treatment Group  
 
As shown Table [IP_ADDRESS] –1, patients randomized to the SOC treatment group will receiv e: 
 
One of the following IV therapie s: 
 
Cefepim e (minimum of 6 doses)  
 
Meropene m (minimum of 6 doses)  
 
Pi[INVESTIGATOR_049]/ta zobactam  (minim um of 8 doses)  
 
Doses given before signing informed consent will be counted if antibiotics remain the same 
(dose and frequency) after signing informed consent.  
 
Gram positive coverage is optional as clinically indicated with IV vanco mycin, daptomycin  or 
linezolid (oral linezolid is allowed) . Daptomycin could be given if there is no evidence of 
pneumonia.  
 
Patients may  receive other additional therapy  as discussed in Section [IP_ADDRESS]. Patients may be 
eligible to switch to outpatien t IV or oral thera py, as discussed in  
Section [IP_ADDRESS].  
 
 
 2020 -0074  
 06/20/2022  
31  
  
 
[IP_ADDRESS]  Other Additional Antibacterial Therapy  
 
Patients in either treatment group may  receive other additional therapy  as needed ( Table [IP_ADDRESS] –
1) at the discretion of the primary  physician or Investigator, per the  MD Anderson Neutropenic  
Fever  Inpatient  Adult  Treatment  Guidelines  (Appendix  II; or Appendix III for patients with 
documented or suspected pneumonia), as follows:  
 
Doubl e Gram-negative coverage should be considered with complicated tissu e-based infections, 
neutropenic enterocolitis, pneumonia, and perirectal in fections; if indicated , add Tobramycin, 
Amikacin Ciprofloxaci n, Minocycline, Tigecycline , Doxycycline , or Bactrim .   
Table [IP_ADDRESS] –1 
 
Additiona l antibacteria l thera py may be adde d at any time during the study  for management of 
complications or if antibacterial re sistanc e is suspecte d or proven  
 
A Switch to a Once-Daily  Gram- Negativ e IV Agent for the Purposes of Outpatient Or Home IV 
Treatment Is Allowed After 48 Hours As Described In Table [IP_ADDRESS] –1 
 
 
Empi[INVESTIGATOR_204074], abdominal symptoms or C. Difficile with Oral 
Vancomycin or  Metronidazole (IV or oral) May Be Added at any time  during the study . 
 
 
Table  9.4.1. 3–1. Investigational  Products  
 
Investigational  
Product  Dosagea and Route   
Form  and Strength   
Supplier  
 Treatment  Grou p:   
Imipenem -
Cilastatin -
Relebactam  500 mg  Imipenem , 500 mg 
Cilastatin  and  250 mg  of 
Relebactam IV over 30 min  
Q6h  Investigational   
FRI 
PLUS /MINUS  one of the following  adjunctive  Gram-positive  therapi[INVESTIGATOR_014]  (optional) : 
 
 
Vancomyci nb 15 mg/kg  (rounded  to nearest  
250-mg dose)  IV q12h   
(+/– 30 min)  
Commercial  Supply  as per FDA  approved  
package  insert   
 
MDA  
 
Linezoli db 600 mg IV (or oral)  q12h    
Commercial  Supply  as per FDA  approved  
package  insert   
MDA  
Optional  for Either  Treatment  Group  (IV Gram-Positive  Adjunctive  Therapy Switch  at any time for 
Patients  With  Suspected  Line  Infections  and/or  Bacteremia)  
 
Daptomyci nb 6-8 mg/kg  IV q24h   
Commercial  Supply  as per FDA  approved  
package  insert   
MDA  
Standard  of Care  (Comparator)  Treat ment Group:   
 2020 -0074  
 06/20/2022  
32  
 ONE  of the following:  
 
Cefepi [INVESTIGATOR_048] 2 g IV q8h  Commercial  Supply  as per FDA  approved  
package  insert   
MDA  
 
Meropenem  1 g IV q8h   
Commercial  Supply  as per FDA  approved  
package  insert   
MDA  
 
Pi[INVESTIGATOR_049]/tazo  
bactam 4.5 g IV q6h   
Commercial  Supply  as per FDA  approved  
package  insert   
MDA  
PLUS /MINUS  one of the following  adjunctive  Gram-positive  therapi[INVESTIGATOR_014]  (optional) : 
 
 
Vancomyci nb 15 mg/kg  (rounded  to nearest  
250-mg dose)  IV q12h   
Commercial  Supply  as per FDA  approved  
package  insert   
 
MDA  
 
 
Linezoli db 600 mg IV (or oral)  
q12h  
  
Commercial  Supply  as per FDA  approved  
package  insert   
 
MDA  
Optional  for Either  Treatment  Group  (IV Gram-Negative  Therapy  Switch  After  at Least  48 Hours  
of IV  Gram-Negative  antimicrobial coverage ) 
 
Ceftriaxone  2 g IV q24h  Commercial  Supply  as per FDA  approved  
package  insert   
MDA  
 
Ertapenem  1 g IV q24h  Commercial  Supply  as per FDA  approved  
package  insert   
MDA  
Optional  for Either  Treatment  Group  (IV Gram-Positive  Adjunctive  Therapy Switch  at any time for 
Patients  With  Suspected  Line  Infections  and/or  Bacteremia)  
 
Daptomyci nb 6-8 mg/kg  IV q24h   
Commercial  Supply  as per FDA  approved  
package  insert   
MDA  
 2020 -0074  
 06/20/2022  
33  
  
 
 
 
Table  9.4.1. 3–1. Investigational  Products  
 
Investigational  
Product  Dosagea and Route   
Form  and Strength   
Supplier  
Optional  for Either  Treat ment Group  (Adjunctive  Double  Gram-Negative  Therapy):   
Tobramyci nc 7 mg/kg  IV q24h  Commercial  Supply  as per FDA  approved  
package  insert   
MDA  
Optional  for Either  Treat ment Group  (Adjunctive  Double  Gram-Negative  Therapy):   
 
Amikaci nc 15 - 20 mg/kg  IV q24h   
Commercial  Supply  as per FDA  approved  
package  insert   
MDA  
Ciprofloxaci nc 400 mg IV q8h Commercial  Supply  as per FDA  approved  
package  insert   
MDA  
Minocyclin  100mg q12h  Commercial  Supply  as per FDA  approved  
package  insert  MDA  
Tigecycline  100 mg/day (day 1 - day 2 on)  
50 mg q12h  Commercial  Supply  as per FDA  approved  
package  insert   
MDA  
Doxycycline  100 mg q12h  Commercial  Supply  as per FDA  approved  
package  insert   
MDA  
Bactrim  5-20mg/kg/day   Commercial  Supply  as per FDA  approved  
package  insert  MDA  
a Dosage s show n for patient s with normal renal/hepatic function. Appropriate dosage modifications for 
renal function  will be made  per Section [IP_ADDRESS] -1 
b Per the MD Anderson  Neutropenic Fever Inpatient Adult Treatment Guidelines ( Appendix II ) or, for patients 
with documented or suspected pneumonia, the MD Anderson  Pneumonia in Adult Patients with Cancer 
Treatment Guidelines ( Appendix I II). 
c As neede d for double Gra m-negative coverage per the MD Anderson  Neutropenic Fever Inpatient 
Adult Treatme nt Guidelines ( Appendix II ). 
  Imipenem Cilastatin Relebactam ; IV = intravenous;  MDA  = MD Anderson ; q6h = every 6 hours; q8h  = every 
8 hours; q12h  = every 12 hours; q24h = every [ADDRESS_243317] doses and time 
of administration defaulted in EPIC system.  
 
Subsequent antibiotic doses may be administered according to MDACC policy (Standard 
28Medication Administration T ime Policy (UTMDACC Institutional Policy # CLN1091) timed 
on the next whole hour. If unable to administer a dose at scheduled time, give the next dose 
ASAP (according to MDACC institutional policy # 1091, Standard medication administration 
Exception list a ttachment). Once the delay has been resolved, re -time future doses to coincide 
with the most recent administration time.  
 
   
[IP_ADDRESS]              Optional Oral or IV Therapy Switch  
 
 
[IP_ADDRESS].[ADDRESS_243318] 48 hours  of  IV gram negative 
antimicrobial coverage if all of the following  criteria  are met: 
 
Oral thera py or IV therapy (for outpatient or home administration) is clinically indicated  
 2020 -0074  
 06/20/[ADDRESS_243319]  been  assessed  
 
Patient has the ability  to maintain oral intake  
 
Patient is clinically  stable  
 
Patient is afebrile  
 
Improvement in clinical signs and symptoms of infection from baseline  
 
Patient has negative blood culture  (taken within past 24 hours)  (for patients with positive blood 
cultures at  baselin e with a gram negative organism ) 
 
.  
 
For Patients Who Are Randomized To SOC , Doses Given Before Signing The Informed Consent 
Will Be Counted If Antibiotics Remain The Same (Dose and Frequency) After Signing The 
Informed Consent.  
 
Exploratory: We will eval uate how often repeat PCT at 48 -72 hours after study drug initiation 
has dropped by ≥ 30 % from baseline (day 0= start of therapy) or PCT level within [ADDRESS_243320] to the clinical judgement to guide antibiotic therapy.  
 
 
[IP_ADDRESS].[ADDRESS_243321] 48 hours of IV gram negative antimicrobial coverage , the patient 
may be switched to an appropriate  combinatio n of oral and/or  IV thera py such as : 
 
Linezolid (oral)  
 
Ampi[INVESTIGATOR_204075]/clavulanate  (oral)  
 
Minoc ycline  (oral)  
 
Ciprofloxacin (oral)  
 
Levofloxacin  (oral)  
 2020 -0074  
 06/20/2022  
35  
  
Cefpodoxime  (Oral)  
 
Trimethoprim/sulfamethoxazole  (oral)  
 
Ceftriaxone  (IV) 
 
Ertapenem  (IV) 
 
Daptomycin (IV) 
 
Vancomycin (I V) 
 
The specifi c combinatio n chose n is at the discretio n of the Investigato r in accordance with local  
SOC and should provide coverage for isolated pathogens and appropriate empi[INVESTIGATOR_98599] l thera py in the 
absence  of microbiological  data.  
 2020 -0074  
 06/20/2022  
36  
 Consult the package inserts, l abels , and local dosin g guideline s regardin g storage, administration, 
maximum doses, contraindications (eg, dru g-drug interactions), warnings, precautions , and 
adverse drug reactions reporte d with the use of oral or IV therapi [INVESTIGATOR_014]. 
 
[IP_ADDRESS]  Duration of Treatment  
 
The total duration of study  therap y will be 2 to 14  days; a minimum of 2 days (ie, 48 hours ) of IV 
gram negative antimicrobial coverage is required . After at least 2 days (ie, 48 hours [of  IV gram 
negative antimicrobial coverage , the Investigator will assess if inpatient IV study drug should be 
continued or a switch to oral or IV therapy  is warrante d (Sectio n [IP_ADDRESS] ). After at least 48 hours 
(ie, 2 days, typi[INVESTIGATOR_204076] 2) of antibiotic  thera py (IV plus oral ), the Investigator 
will assess if inpatient  IV study  drug or oral or IV  switch thera py should be continued or if all 
therapy  should be discontinued.  
 
Duratio n of thera py is at the discretio n of the Investigator , considerin g clinica l response, presence 
of clinically  and /or microbiologically  documented infections, and signs of bone marrow 
recover y. 
 
An assessment  of clinical  outcome  will be made  at the end of all study therap y as defined in 
Section  [IP_ADDRESS].  
 
9.4.[ADDRESS_243322] Imipenem -Cilastatin -Relebactam  contains  Imipenem , Cilastatin  and 
Relebactam , which will be administered together in a single i nfusion bag. A single vial filled 
with the sterile crystalline form of Imipenem (500 mg ), cilastatin 500mg,  and the sterile 
crystalline form of Relebactam  (250mg ) for IV administration. The crystalline powders are 
reconstituted using saline or various dext rose solution  for Injection, resulting in a concentrate 
solution. An amount of this solution, corresponding  to the dose to be administered, is withdrawn 
from the vial and transferred into an infusion bag containing [ADDRESS_243323] of appropriate diluents is as follows:  
• 0.9% Sodium Chloride Injection, USP  
• 5% Dextrose Injection, USP  
• 5% Dextrose Injection, USP + 0.9% Sodium Chloride Injection, USP  
• 5% Dextrose Injection, USP + 0.45% Sodium Chloride Injection, USP  
• 5% Dextrose Injection, USP + 0.225% Sodium Chloride Injection, USP  
RECARBRIO has low aqueous solubility. To ensure complete dissolution of RECARBRIO it is  
important to adhere to the following instructions:  
Step 1) For diluents available in 100 mL prefilled infusion bags, proceed to step 2. For diluents 
not available in 100 mL prefilled infusion bags, aseptically withdraw 100 mL of the desired 
diluent and transfer it to an empty infusion bag, th en proceed to step 2.  
 2020 -0074  
 06/20/2022  
37  
 Step 2) Withdraw 20 mL (as two 10 mL aliquots) of diluent from the appropriate infusion bag 
and constitute the vial with one 10 mL aliquot of the diluent. The constituted suspension is for 
intravenous infusion only after dilution in a n appropriate infusion solution.  
Step 3) After constitution, shake vial well and transfer resulting suspension into the remaining 80 
mL of the infusion bag.  
Step 4) Add the second [ADDRESS_243324] ete transfer of vial contents; repeat transfer of the resulting suspension to the infusion 
solution before administering. Agitate the resulting mixture until clear.  
Constituted solutions of RECARBRIO range from colorless to yellow. Variations of color with in 
this range do not affect the potency of the product.  
Parenteral drug products should be inspected visually for particulate matter and discoloration 
prior to administration, whenever solution and container permit. Discard if discoloration or 
visible part icles are observed.  
 
The above instructions for preparation of RECARBRIO solution for intravenous administration 
must be followed for all patients, irrespective of the intended patient’s renal function. The 
volume of this prepared  RECARBRIO solution to be administered to patients is determined 
based on renal function [see Dosage  and Administration ]. 
 
Preparation of RECARBRIO Solution for Intravenous Administration in Patients with Renal  
Impairment  
For patients with renal impairment, prepare a reduced dose of RECARBRIO (1 gram, 0.75 
grams, or  0.5 grams) by [CONTACT_66110] a 100 mL solution containing 1.25 grams  (as described above) 
then withdrawing and discarding the excess according to Table 2.  
Table 2: Preparation of Reduced RECARBRIO Doses for Intravenous Admin istration in Patients  
with Renal Impairment  
 
 
 
Creatinine 
Clearance 
(mL/min)   
Dosage of RECARBRIO 
(imipenem/cilastatin/relebactam
) After preparation as 
instructed above, remove 
from the [ADDRESS_243325]  Resulting v olume 
that provides the 
indicated reduced 
dose 
60 to 89  1 gram (imipenem 400 mg, 
cilastatin  
400 mg, and relebactam 200 
mg) 20 mL  80 mL  
 
30 to 59  0.75 grams (imipenem 300 mg, 
cilastatin 300 mg, and 
relebactam  
150 mg)   
[ADDRESS_243326] on 
hemodialysis  0.5 grams (imipenem 200 mg, 
cilastatin 200 mg, and 
relebactam  
100 mg)   
60 mL   
40 mL  
 
 2020 -0074  
 06/20/2022  
38  
  
With the exception of Imipenem -Cilastatin -Relebactam  all other study drugs (IV or oral) will be 
commercially labeled. All inpatient IV study drug and oral and IV therapi[INVESTIGATOR_204077] a 
secure place under appropriate storage conditions, as specified on the drug labeling and  package 
insert.  
 
Upon completion of the study or termination of the site, all used and unused study drugs that 
were supplied by [CONTACT_204104] . 
 
9.4.[ADDRESS_243327] (CTC) website, developed by [CONTACT_204105].  
At the end of the study, 50% patients will be divided equally at the end of the study between both 
arms. If the patient is started on one of the three agents, we will co ntinue the same agent if he is 
assigned to SOC arm. The choice of the antibiotic will be kept at the discretion of the primary 
team.  
 
Patients in SOC arm will be analyzed as one treatment group in the intent to treat analysis and 
other analysis.   
 
At the time of signing the ICF and consenting to participate in this stud y. The first patient to sign 
the ICF at the study  center will be assigned the first accession number, and each  subsequen t 
patien t will be assigned the next sequential numbe r. This pat ient identification number will be 
used to identify  the patient at all phases of the stud y. 
 
 
9.4.[ADDRESS_243328] are shown in Table [IP_ADDRESS] –1 and, if applicable , in 
the MD Anderson  Neutropeni c Feve r Inpatient Adult Treatment Guidelines ( Appendix II ) or, for 
patients with documented or suspected pneumonia, in the MD Anderson  Pneumonia in Adult 
Patients with Cancer Treatment  Guidelines  
(Appendix  III). 
 
The dose of Imipenem -Cilastatin -Relebactam  that was selected for this study was based  on 
clinical trial for the treatment of cIAI and cUTI table II  
 
The dosage s of the other investigationa l product s are considere d SOC and are used in current 
treatment of febrile neutropenic patients at MD Anderson , as shown in  the MD Anderson  
Neutropeni c Feve r Inpatient Adult Treatment Guidelines (Appendix II ) or, for patients with 
documented or suspected pneumoni a, in the MD Anderson  Pneumonia in Adult Patients with 
Cancer Treatment Guidelines (Appendix III). 
 
9.4.5  Selection and Timing of Dose for Each Patient  
 
Investig ational products will be administered per  Table [IP_ADDRESS] –1 and, if applicable, per the MD 
Anderson  Neutropenic Fever  Inpatient Adult Treatment Guidelines  (Appendix  II) or, for patients 
 2020 -0074  
 06/20/2022  
39  
 with docume nted or suspected pneumonia, in the MD Anderson  Pneumonia in Adult Patients 
with Cancer Treatment Guidelines ( Appendix  III). 
 
[IP_ADDRESS]  Dose Adjustments for Imipenem -Cilastatin -
Relebactam  
 
In the case of renal impairment, at any time, the dose of Imipenem -Cilastatin -Relebactam  
(including the initial dose) may  be adjusted by [CONTACT_204106] [IP_ADDRESS] –1. At any time, the d ose of  Imipenem -Cilastatin -Relebactam  may be 
readjusted to the appropriate dosag e when renal functio n improves . If a patient’s estimated CrCl 
(as calculate d using th e Cockcrof t-Gault formula  [Section [IP_ADDRESS] ]) decrease s to ≤ 30 mL/min 
during the treatment period, the  Study  Physician should  be contact[CONTACT_204107]  ≤ 30 mL/min. 
 
 
 
 
 
 
Table  9.4.5. 1–1.  Dosage  Adjustments  for Renal  Impairment  
 
Dosage Adjustments In Patients With Renal Impairment  
Dosage adjustment is recommended in patients with renal impairment. Patients who have a CLcr 
less than 90 mL/min require dosage reduction of RECARBRIO (Table I). For patients with 
fluctuating renal function, CLcr should be monitored.  
 
Table I: Dosage of RE CARBRIO for Adult Patients with Renal Impairment  
Estimated CLcr 
(mL/min)a Recommended Dosage of RECARBRIO 
(imipenem/cilastatin and relebactam) (mg)b Dosing Interval  
60 to 89  1 gram (imipenem 400 mg, cilastatin 400 mg, 
and relebactam 200 mg)  Every 6 hours  
30 to 59  0.75 grams (imipenem 300 mg, cilastatin 300 
mg, and relebactam 150 mg)  Every 6 hours  
15 to 29  0.5 grams (imipenem 200 mg, cilastatin 200 
mg, and relebactam 100 mg)  Every 6 hours  
End Stage Renal 
Disease (ESRD) on 
Hemodialysisc 0.5 grams (imipenem 200 mg, cilastatin 200 
mg, and relebactam 100 mg)  Every 6 hours  
aCLcr calculated using the Cockroft -Gault formula  
bAdminister by [CONTACT_204108] 30 minutes.  
cAdministration should be timed to follow hemodialysis.  
RECARBRIO is provided as a sing le vial in a fixed -dose combination; the dose for each 
component will be adjusted equally during preparation [see Preparation of RECARBRIO 
 2020 -0074  
 06/20/2022  
40  
 Solution for Intravenous Administration in Patients with Renal Impairment].  
 
Patients with CLcr less than 15 mL/min should not receive RECARBRIO unless hemodialysis  is 
instituted within 48 hours. There is inadequate information to recommend usage of 
RECARBRIO for patients undergoing peritoneal dialysis .  Imipenem, cilastatin, and relebactam 
are cleared from the circulation  during hemodialysis. For patients maintained on hemodialysis, 
administer RECARBRIO after hemodialysis and at intervals timed from the end of that 
hemo dialysis session.  
 
[IP_ADDRESS]  Dose Adjustments - Other Investigational Products  
 
For all other investigational products, appropriate dosage modifications for renal function will  be 
made  per the respective  package  insert  or institutional guidelines.  
 
 
9.4.6  Blinding 
 
This study  will be conducted as an open -label investigation; no blinding of assigned treatment 
will occur.  
 
 
9.4.7  Unblinding  
 
Not applicabl e. 
 
9.4.8  Prior and Concomitant Therapy  
 
All prior (taken or received within [ADDRESS_243329] dose of IV study  drug) and 
concomit ant (take n durin g the study) medications , includin g but not limite d to, antimicrobials (ie, 
antibacterials, antivirals, antifungals, antiparasitics), ove r-the-counter medications (eg, vitamins, 
herbal medications), and parenteral nutrition,  will be documen ted on the appropriate screens of 
the eCRF  (concomitant meds will be captured in subjects medical record in Epic) . 
 
Concomitant use of the following is not permitted: 1) potentially  effective s ystemic antibacteria l 
thera py; 2) any drug known to exhibit a contraindicated dru g-drug interactio n with any of the 
study therapi[INVESTIGATOR_34405] a labele d contraindicatio n to use of any study  therapi[INVESTIGATOR_014].  
 
All other concomitant medications and nutrients necessary  for the health and well -being of the 
patient are permitted.  
 
9.4.9  Monitoring Treatment Compliance  
 
Treatment compliance will be  closely  monitored  by [CONTACT_108888], time, and whether or not 
each dose of inpatient  IV study drug or IV switch therapy  was infused and,  if applicable,  
whether  or not each intended  dose of oral switch therapy  was taken.  
 
 
 
9.5 EFFICACY AND SAFETY VARIABLES  
 
 2020 -0074  
 06/20/2022  
41  
  
9.5.1  Primary and Secondary Efficacy Assessments  
 
 
Primary Efficacy Assessment  
 
The Investigator’s assessment of clinical response will be used to determine the primary efficacy  
assessment. The Investigator should consider the entirety  of the patient’s clinical course and 
current status, including  an evaluation of infection signs and symptoms  (eg, fever, neutropenia) , 
radiological findings (if applicable), and ph ysical examination in order to classify  the patient’s 
clinical response at EOIV according to  the definitions listed in Table [IP_ADDRESS] –1. The investigator 
could rely on p hysical ex am performed  by a professionally trained physician or health 
professional licensed to perform physical examinations .  
The investigator will use the  serial  PCT levels drawn at baseline and at [ADDRESS_243330] spectrum agents (Imipenem/ Cilastatin/ Relebactam & SOC).  
 
 
Secondary  Efficacy  Assessmen ts 
 
Clinical Assessments  
The Investigator’s assessment of clinical response  at EOIV , TOC, and LFU  will be used to 
determine the secondary  clinical efficacy  endpoints according to the definitions listed in  Table 
[IP_ADDRESS] –1. 
 
 
Microbiologica l and Molecular Assessments  
A patien t’s microbiological  response  at EOIV, TOC , and LFU  will be determined 
programmatical ly based on individual outcomes for each baseline pathogen  accordin g to the 
definitions listed in  Table [IP_ADDRESS] –1. 
 
 
[IP_ADDRESS]  Microbiological Assessments  
 
 
Blood Samples for Culture  
 
Blood samples for culture  will be obtaine d at the following  time points , preferab ly before the 
next scheduled dose of study  antibiotics  is administere d: 
 
Baseline  
 
Study  Days 1 to ≤ 14:  every  other  day until temperatur e is ≤ 100.4 °F (38.0°C) and blood cultures 
are negative  and PCT is < 0.25 or dropped by 30% or more within 48 -72 hours compared to 
baseline on Day 0 (start of therapy). PCT will be collected at baseline and at 48 -72 hours after 
study drug initiation.  
 
EOIV : if baseline cultures were positive  (to determine microbiologica l respons e) 
 
TOC and LFU: as clinically  indicated  per the discretion  of the Investigato r (eg, if clinical 
 2020 -0074  
 06/20/2022  
42  
 worsening  and/or persistenc e of fever or other signs or symptoms consistent with clinical 
failur e) 
 
Blood culture s should be repeated upon knowledge of a positive result from any  visit until 
sterilization is confirmed.  
 
When blood culture s are required , 1-[ADDRESS_243331] 1-2 blood cultures from separate  venipuncture  sites.  
 
Cultur e, organism  identificatio n, and susceptibility  testing  will be conducted at the local 
laborator y. All pathogens will be tested for susceptibility  to all drugs  used.  
 
Microbiologica l sample s for blood cultures will be collected, process ed, and stored in 
accordance with local procedures (refer to Microbiology  Manual) . 
 
 
 
 
 
  
Other Samples for Culture  
 
Culture specimens from other sites of suspected infection should be obtained as clinical ly 
indicated.  
 
Culture , organis m identification , and suscepti bility  testing will be conducted at the local 
laborator y. All pathogens will be tested for susceptibility  to all drugs  used.  
 
Microbiologica l sample s will be collected, processed, and stored in accordance with local 
procedures (refer to Microbiology  Manual) . 
 
 
[IP_ADDRESS]  Clinical Outcome of the Infection  
 
Per the Schedule of Assessments and Procedures (Table 2–1), the Investigator  or sub-
investigator  is to assess  the Clinical Outcome at EOIV, TOC and LFU.  
 
 
9.5.2  Safety Assessments  
 
 
Throughout the clinical trial, each patient will be observed for adverse reactions.  All patients 
will be monitored for the development of study -related adverse events through the entire study 
period including the thirty (30) days following the last dose o f study drug. Any serious, 
unexpected adverse event(s) will be reported to the funder  and IRB per policy, and reported to 
the FDA accordingly. Patients who have received at least one dose of the study drug will be 
included in the safety analysis. Patients who withdraw consent prior to receiving any dose of 
study drug, will not be included in the analysis and will be replaced by [CONTACT_204102]. 
Evaluation done by [CONTACT_204109] 
 2020 -0074  
 06/20/2022  
43  
 acceptable.  
 
9.5.2 .1 Adverse Events  
 
Recording of Adverse Events.   
An adverse event is the appearance or worsening of any undesirable sign, symptom, or medical 
condition occurring after starting the study drug even if the event is not considered to be related 
to study drug . Medical conditions/diseases present before starting study drug are only considered 
adverse events if they worsen after starting study drug. Abnormal laboratory values or test results 
constitute adverse events only if they induce clinical signs or symptom s, are considered clinically 
significant, or require therapy.  
 
Reportable a dverse event s for this protocol will be documented into the Adverse Events log 
(source document) and entered into the case report form  in RedCap according to the Recommended 
Adverse Event Guidelines for Phase II  Protocols (please refer to chart on page 46). The patients’ 
records will be reviewed and only reportable AEs (AEs of any grade  that are possibly, probably 
and definitely related to the stu dy drug , and any AE grade 3 or above regardless of their attribution 
to study drug) will be documented in the AE log and case report form ”. The Investigator or 
physician designee is responsible for verifying and providing source documentation for all 
repor table adverse events and assigning the attribution for each event for all subjects enrolled on 
the trial. AEs not recorded on the AE log and case report form are considered grade 1 or 2 and 
unrelated or unlikely related to the study drug.  This recording  will apply to all patients enrolled on 
the protocol including future , current  and previously enrolled patients. Labs that are not deemed  
clinically significant  by [CONTACT_204110].  Additionally, the Investigator 
is responsible for  providing appropriate treatment for the event and for adequately following the 
event until resolution for all adverse events for subjects enrolled . 
 
Version 5.0 of the Common Toxicity Criteria for adverse events will be used to assess AEs and 
SAE (please refer to Section  [IP_ADDRESS] ) 
• Attribution  - the determination of whether an adverse event is related to a medical 
treatment or procedure.  
• Definite  - the adverse eve nt is clearly related to the investigational agent(s).  
• Probable  - the adverse event is likely related to the investigational agent(s).  
• Possible  - the adverse event may be related to the investigational agent(s).  
• Unlikely  - The adverse event is doubtfully r elated to the investigational agent(s).  
• Unrelated  - The adverse event is clearly NOT related to the investigational agent(s).  
 
 
Study subjects should be instructed to report all adverse events to the Investigator.  In addition, 
the Investigator should seek  to elicit any clinical or objective reactions by [CONTACT_71997], as appropriate, by [CONTACT_5148].  Information on all adverse events should be recorded on the 
case report form.  All clearly related signs, symptoms and abnormal diagnostic procedur es 
should be grouped together and recorded as a single diagnosis.  The component parts of the 
diagnosis may be listed for verification.  For each adverse, the Investigator is to assess the 
severity of the reaction, and to determine the relationship to stud y drug.  In addition, the duration 
 2020 -0074  
 06/20/2022  
44  
 will be noted, and whether intermittent or continuous  also documentation of the outcomes and 
what was done with study drug is needed.  
Events not included in the NCI CTCAE will be scored as follows:  
• Grade 1: Mild: discomfort present with no disruption of daily activity, no treatment 
required beyond prophylaxis.  
• Grade 2: Moderate: discomfort present with some disruption of daily activity, require 
treatment.  
• Grade 3: Severe: discomfort that interrupts normal daily act ivity, not responding to first 
line treatment.  
• Grade 4: Life Threatening: discomfort that represents immediate risk of death  
 
 
 
Pleas e note medica l procedur es scheduled prior  to consenting,  but occurring  during  the study  
should not be captur ed as AEs, but  should be listed in the medical history  if related to a pre-
existing conditio n. 
 
Any worsening  of the infection  under  study becaus e of lack of therapeuti c effec t of any study  
drug is captured as an efficacy  analysis variable  and is not to be considered  an AE, unles s the 
even t is an SAE  resul ting in de ath (Section [IP_ADDRESS] ). 
 
Pregnancies  should  not be automatical ly assesse d as AEs. 
 
[IP_ADDRESS]  Causality Assessment  
 
The Investigator or physician designee is responsible for verifying and providing source 
documentation for all adverse events and assigning the attribution for each event for all subjects 
enrolled on the trial. Assessments done by [CONTACT_204111].  
 
Is there a reasonable possibility  the investigatio nal produc t cause d the event? 
 
 
Yes: There Is Evidence To Suggest A Causal Relationship Between The Investigational 
Product and The Ae; Ie: 
 
○ There is a reasonable temporal relationship between the investigational product and the event , 
and/or 
 
○ The event is unlike ly to be attributed to under lying/concurrent disease, other investigational 
products, or other factors, and/or  
 
○ Positive dechallenge a nd/or rechallenge exist  
 
No: There Is No Evidence To Suggest A Causal Relationship Between The 
Investigational Product and The Ae, Ie: 
 
○ Ther e is no reasonable temporal relationship between the investigational product and the event , 
 2020 -0074  
 06/20/2022  
45  
 or 
 
○ The patien t did not take the investigational product, or  
 
○ The event is like ly to be attributed to under lying/concurrent disease, other investigational 
products, or other factors, or  
 
○ The event is common ly occurring in the (stu dy) population independent of investigational 
product exposure  
 
 
[IP_ADDRESS]   
Serious Adverse Event (SAE) Reporting Requirements for M D Anderson Sponsor ed 
Single Site IND Protocols  
 
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either 
the investigator or the sp onsor, it results in any of the following  
outcomes:  
  
• Death  
• A life -threatening adverse event  
• Inpatient hospi[INVESTIGATOR_1081]  
• A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions.  
• A congenital anomaly/birth defect.  
  
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_3767] a serious adverse drug experience when, based upon 
appropriate medi cal judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition. 
Examples of such medical events include allergic bronchospasm requiring intensive treatment in 
an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse (21 CFR 312.32).  
  
• Important medical events as defined above, may also be considered serio us adverse 
events. Any important medical event can and should be reported as an SAE if deemed 
appropriate by [CONTACT_079] [INVESTIGATOR_9476], IND Office.  
• All events occurring during the conduct of a protocol and meeting the definition of a SA E 
must be reported to the IRB in accordance with the timeframes and procedures outlined 
in “The University of [LOCATION_007] M. D. Anderson Cancer Center Institutional Review Board 
Policy on Reporting Adverse Events for Drugs and Devices”.  
• Serious adverse events wi ll be captured from the time of the first protocol -specific 
intervention, until [ADDRESS_243332] dose of drug, unless the participant withdraws 
consent.  
• Serious adverse events must be followed until clinical recovery is complete and 
laboratory tests  have returned to baseline, progression of the event has stabilized, or there 
 2020 -0074  
 06/20/2022  
46  
 has been acceptable resolution of the event.  
• All SAEs, expected or unexpected/ initial or follow up, must be reported to the IND 
Office within 5 working days of knowledge of the event  regardless of the attribution . 
• Death or life -threatening events that are unexpected, possibly, probably or definitely 
related to drug must be reported (initial or follow up) to the IND Office within 24 hours 
of knowledge of the event  
• Additionally, a ny serious adverse events that occur after the [ADDRESS_243333] be reported to the IND Office. This may include the 
development of a secondary malignancy.  
• The electronic SAE application (eSAE) will be utilized  for safety reporting to the IND 
Office and MD Anderson IRB.  
• All events reported to the supporting company must also be reported to the IND Office  
  
Reporting to FDA:  
• Serious adverse events will be forwarded to FDA by [CONTACT_14211] 21 
CFR 3 12.32.  
  
It is the responsibility of the PI [INVESTIGATOR_195697], Good Clinical Practices, the 
protocol guidelines, the sponsor’s guidelines, and Institutional Revi ew Board policy.   
 
 
 
 
Emergency room visits that do not result in hospi[INVESTIGATOR_204078].  
 
Preplanned hospi[INVESTIGATOR_602] (eg, elective procedures for preexisting conditions that did not 
worsen, such as cosmetic surgery and hysterectomy) are excluded from SAE reporting.  
 
Any worsening of the infection under study because of lack of therapeutic effect of any study 
drug is captured as an efficacy analysis variable and is not to be considered an SAE, unless the 
event results in death.  
Pregnancy will be reported  to the IND Office  via eSAE application as “Other Important Medical 
Event  
 
This study will collect adverse events according to phase II guidelines on the table below:  
 2020 -0074  
 06/20/2022  
47  
  
 
Reporting to the sponsor:  
Serious Adverse Event and Suspected Unexpected Serious Adverse Reaction,  Potential Incident 
Reporting:  Principal Investigator [INVESTIGATOR_204079]’s Global “[COMPANY_006] GPV”) group, any SAE 
or S[LOCATION_003]R,  including, but not limited to, all initial and follow -up information involving any Study 
subject in the Study. Notification shall be in the form of a completed CIOMS I/MedWatch (or 
other mutually agreed upon format such as eSAE ) within two (2) business da ys of but not longer 
than three (3) calendar days of receipt of the information. The phrase “business days” means a day 
in which Institution has regular business operations and would exclude weekends and holidays 
observed by [CONTACT_16277]’s administrative st aff. This information shall be transmitted to [COMPANY_006]. All 
information shall be transmitted in the English language and contain the reporter’s name [CONTACT_204130].  
 
The below terms shall be defined as follows:  
 
“Adverse Event ” or “ AE” shall mean any untoward medical occurrence in a Study subject who is 
administered the Study Drug regardless of whether or not a causal relationship with the Study 
Drug exists. By [CONTACT_204112], an AE can be any unfavorable and 
unintended sign (for example, an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of the Study Drug.  
 
“Serious Adverse Event ” or “ SAE ” shall mean any untoward medical occurrence in a Study 
subject who is administered the Stu dy Drug that results in death, a life - threatening drug 
experience, requires inpatient hospi[INVESTIGATOR_1081], results in 
persistent or significant disability/incapacity, or is a congenital anomaly/birth defect, cancer,  or is 
a new cancer if the cancer is the condition of the study, or overdose. Other important medical 
events that may jeopardize the patient or may require intervention to prevent one of the outcomes 
listed previously should also be considered “serious”.  

 2020 -0074  
 06/20/2022  
48  
  
“Suspected Unexpected Serious Adverse Reaction ” or “ S[LOCATION_003]R ” shall mean any Serious 
Adverse Event, the nature, severity or frequency of which is not consistent with information in the 
most current investigator’s brochure, or with respect to a marketed product the most current 
Summary of Product Characteristics (SPC) or Package Insert.  
 
 
[IP_ADDRESS]  Clinical Laboratory Determinations  
 
Blood sample and urine culture/urine analysis (when clinically needed) will be collecte d 
according  to the Schedul e of Assessment s and Procedure s (Table 2-1). Specific labs important to 
the analysis will only be entered in REDC ap and include procalcitonin, white blood cell count 
(WBC), absolute neutrophil count (ANC), hemoglobin, platelet count, alanine aminotransferase 
(ALT), albumin, alkaline phosphatase, creatinine, and total bilirubin.  
 
Women of childbearing potential (inclu ding those who are fewer than 2 years postmenopausal) 
will be required to have a serum or urine pregnancy test at baseline (within 5 days ). The test 
must be negative before randomization. If the serum test results cannot be obtained before 
randomization, a urine pregnancy test may be used for enrollment.  
 
The following clinical laboratory  level s will be measure d (those marked with an asteris k [*] are 
required for eligibilit y): 
 
Hemato logy:  Basophil s (absolut e coun t and %), eosinophil s (abso lute coun t and %), e rythrocyte 
count, hematocrit,  hemoglobin, leukoc ytes (absolute count and differential), l ymphoc ytes 
(absolute count and %), monoc ytes (absolute coun t and %), neutrophil s (absolut e count * and  %), 
immature  neutrophils (bands ; %), platelet count, red blood cell indices (mean corpuscular 
volume,  mean  corpuscular  hemoglobin,  and mean  corpuscular  hemoglobin concentration)  
 
Chemistry :  Albumin, A LT*,  bilirubin * (total), blood urea nitrogen , calcium , creatinin e*, 
electrol ytes (ie, bicarbonate, chloride,  potassium,  sodium ), glucose , Procalcitonin (which will be 
repeated between 48 -72 hours after initiation of therapy).   
 
Urinalysis  if clinically indicated : Appearance (color, clarit y), bilirubin, blood,  glucose, 
ketones, leukoc yte esterase, nitrite, pH, protein, specific gravit y, urobilinoge n, and urine 
microsco py (ie, red blood cells, white blood cells, casts, cr ystals, b acteria, yeast cells, parasites)  
 
Other :  pregnancy  test* 
The MD Anderson  local laboratory  will be used to evaluate all urine and blood sample s. Results 
from unscheduled laboratory  tests will not be collected, unless ass ociate d with an 
SAE  or AE leading  to discontinuation  of IV study drug. EXCEPTION: At the discretion of the 
Investigator , unschedule d ANC value s will be recorded  as clinical ly indicated whil e on oral or IV 
Switch  therapy  (ie, betwee n EOIV and TOC).  
 
Any abnormal laboratory test possibly  attributable to inpatient IV study drug will be repeated at 
appropriate intervals until  stabilizatio n. 
 
[IP_ADDRESS]  Vital Signs, Body Weight, and Height  
 
 2020 -0074  
 06/20/2022  
49  
 Vital  signs  will be recorded  at every  visit; t he parameter s are: 
 
Bloo d pressur e: systolic and diastolic  
 
Pulse rat e 
 
Respi[INVESTIGATOR_204080] : patients with respi[INVESTIGATOR_204081] s ymptoms  
 
Temperatur e: recor d highest daily  temperature  
 
Body weight and height will be measured at baseline. If height or weight is not obtained , the last 
known or stated height and weight may  be used.  
 
[IP_ADDRESS]  Chest Radiography  
 
A chest x-ray (CXR)  (posteroanterio r and lateral) or chest  computed tomography  (CT) scan will 
be obtaine d at baselin e for patients with respi[INVESTIGATOR_204082].  If the patien t’s cond ition 
does not allow for a standard posteroanterior and lateral examination, a  portable  anteroposterior  
CXR  is acceptable.  Chest radiography  will be obtained postbaseline, ie, at EOIV, TOC, or LFU 
if clinically  indicated.  
 
[IP_ADDRESS]  Physical Examination  
 
A complet e physical examination will be conducte d by a professionally  trained  physician o r 
healt h professiona l license d to perfor m physical examinations.  
 
9.5.3  Schedule of Assessments  
 
The schedule of study  assessments and procedures  is tabulated by  [CONTACT_126722] 2–1. The 
descriptions of the procedures t o be performed at each visit are provided below.  
 
[IP_ADDRESS]  Baseline  
 
Baseline procedures must be comple ted within  [ADDRESS_243334] dose of  
inpatient IV study  drug.  Any protocol -required eligibility  laboratory  evaluations alrea dy done as 
part of the patien t’s regular medical care within  [ADDRESS_243335] to be repeated to determin e patien t eligibilit y. 
 
At baselin e, informed consent will be obtained,  a review  of inclusion/exclusion  criteria will be 
conducte d to determin e the patien t’s eligibility  for enrollment,  and study procedures will be 
reviewed with the  patien t and/or  caregiver , and the legally  authorized representativ e (if different 
from the caregive r). After signin g the ICF, the patient will be assigne d a uniqu e PID number  (or 
accession number) (see Section 9.4.3 ). If, after revie w of the inclusion/exclusion criteri a, it is 
determined that the patient is eligible to enter the stu dy, the patient will be randomized accordin g 
to the randomization procedures in  Section 9.4.3.  
 
At baselin e, the following procedures will be performed:  
 
Obtai n writte n informe d consen t per Section 5.3 
 2020 -0074  
 06/20/2022  
50  
  
Verify  that inclusion criteria are met and none of the exclusion criterion apply  
 
Obtai n medica l and surgical history  including all active conditions and all conditions diagnosed 
within the pr evious 3 months  
 
Abnormal baseline labs will not be captured as baseline AEs or medical history as deemed not 
clinically significant pertaining to our protocol. A changing in the grade of the abnormal labs 
during study treatment will be captured as AEs if clinically significant.  
 
Obtain height and weight (if height or weight is not obtained , use the last known or stated height 
and weight)  
 
Perfor m CXR (eg, portable anteroposterior film) or chest CT for patients with respi[INVESTIGATOR_204083] (per Section [IP_ADDRESS])  
 
Perfor m complet e physical examination  
 
Record  vital signs  (blood  pressure  and pulse  rate, respi[INVESTIGATOR_2842], oxygen saturation [if 
applicable], highest daily temperature)  
 
Recor d prior medications , includin g antimicrobials (ie, antibacterials,  antivira ls, antifunga ls, 
antiparasiti cs), over-the-coun ter medications (eg, vitamins, herbal medications),  and parenteral  
nutrition  taken  or received  within [ADDRESS_243336] infectio n signs and symptoms  
 
Laboratory  assessments:  
Collect blood and urine samples for clinical laboratory  determinations per Section [IP_ADDRESS].  
 
Record ANC  
 
Collect blood sample for pregnancy  test (female s of childbear ing potential onl y, includin g those 
who are fewe r than 2 years postmenopausal); ensure test is negative before randomization. If the 
serum test results cannot be obtained before randomization  within [ADDRESS_243337] 
may be used for enrollment  
 
Estimate CrCl using the followin g Cockcroft -Gault formula (use actual body weight and 
conventional units;  if weight  is not obtained , use the last know n or stated weight ): 
 
Males: CrCl= (140 – age in years) X weight in kg / 72 X serum creatinine (mg/dL)  
 
Female: CrCl= 0.85 X (140 -age in years) X weight in kg / 72 X serum creatinine (mg/dL)  
Microbiological assessments:  
 
 Collect blood sample for culture  and PCT  per Section [IP_ADDRESS]  (See pages 33 -34). 
 
 If clinical ly indicated , collect other samples for culture  per Sectio n [IP_ADDRESS]  
 2020 -0074  
 06/20/2022  
51  
  
Randomize patient after verif ying that the patient meets all study  inclusion criteria and  no 
exclusion  criteria  
 
 
[IP_ADDRESS]  Study Days 1 To ≤ [ADDRESS_243338] administered. Baseline and 
Study day 1 assessment could be combined if  they occur on the same calendar day . 
 
On Study  Days 1 to ≤ 14,  administer study  therapy  to all patients and conduct the followin g 
assessments and procedures dai ly while the patient is hospi[INVESTIGATOR_204084] g IV study drug , 
unless otherwise specified:  
 
Perform complete physical examination twice a week after first dose of inpatient IV study 
drug, at least every [ADDRESS_243339]  vital signs  (blood  pressure  and pulse  rate a, respi[INVESTIGATOR_2842], oxygen saturation [if 
applicable], highest daily temp erature)  
 
Record new concomitant medicati ons 
 
Review and record AEs and SAEs  
 
Evaluat e and recor d infectio n signs and symptoms  
 
Laboratory  assessments:  
 
Collec t blood and urine sample s for clinical laboratory  determinations (Sectio n [IP_ADDRESS] ) if 
clinically  indicated  
 
On Study  Day 7 +/- [ADDRESS_243340] blood and urine samples for 
clinical laboratory  determinations (Section  [IP_ADDRESS] ). 
 
Recor d ANC a minimum of 3 times per week while on study  therapy  (IV or oral)  
 
Recor d estimate d CrCl every [ADDRESS_243341] dose of inpatient IV study drug 
beginnin g on Stud y Day 1 
 
Microbiological assessments:  
 
Obtai n blood sample s (per Sectio n [IP_ADDRESS] ) for culture every  other  day until temperature  is ≤ 
100.4°F (38.0°C)  and culture s are negative  
 
If clinical ly indicated, collect other samples for culture per Section  [IP_ADDRESS].  
 
 2020 -0074  
 06/20/2022  
52  
 Administer study  therapie s per Sectio n 9.4.1 and Table [IP_ADDRESS] –1 
 
 
[IP_ADDRESS]  End o f Inpatient  Intravenous Therapy  
 
Conduct EOIV assessments within [ADDRESS_243342] dose of inpatient IV study  drug, and conduc t the following assessments and 
procedures in all  patien ts, unles s otherwis e specified:  
 
If clinical ly indicated , perform CXR (eg, portable anteroposterior film) or chest CT for patients 
with respi[INVESTIGATOR_204085] m complet e physical examination  
 
Recor d vital signs (bloo d pressur e and pulse rate,  respi[INVESTIGATOR_92196], oxygen saturation [if 
applicable], highest daily temperature)  
 
Record new concomitant medications  
 
Review and record AEs and SAEs  
 
Evaluat e and recor d infectio n signs and symptoms per Sectio n [IP_ADDRESS]  
 
Assess clinical  outcome  per Section  [IP_ADDRESS]  
 
Laboratory  assessments:  
 
Collect blood and urine samples for clinical laboratory determinations  
(Sectio n 9.5.2. 5) if laboratory tests for EOIV is perform ed ≥ 24 hours prior to EOIV  (if 
applicable)  
 
Record ANC  
 
If clinical ly indicated, record estimated CrCl  
 
For patients on  oral or IV  therap y: At the discretion of the Investigator , record ANC as clinical ly 
indicate d (ie, during an unscheduled visit betwee n EOIV an d TOC)  
 
Microbiological and molecular (PCT) assessments:  
 
If baseline blood cultures were positive, repeat blood cultures (per Section [IP_ADDRESS] ) 
 
If clinical ly indicated , collec t other sample s for cultur e (per Section  [IP_ADDRESS] ) 
 
[IP_ADDRESS]  Test-of-Cure (Toc)  
 
Conduct TOC assessments in person at any  time betwee n Study Days 21 and 28 (ie, 21 to 28 
days after the start of inpatient IV study drug).  
 2020 -0074  
 06/20/2022  
53  
  
For patient s who were switche d to oral or IV therap y: Assess if oral or IV thera py was complete d 
and if not, recor d date of and reason for discontinuation  
 
If clinical ly indicated, perform CXR (eg, portable anteroposterior film) or chest CT for patients 
with respi[INVESTIGATOR_204085] m complet e physical examination  
 
Record  vital signs  (blood  pressure  and pulse  rate, respi[INVESTIGATOR_2842], oxygen saturation [if 
applicable], highest daily temperature)  
 
Recor d new concomitant medications  
 
Review and record AEs and SAEs  
 
Evaluat e and record infectio n signs and symptoms per Sectio n [IP_ADDRESS]  
 
Asses s clinica l outcom e per Section [IP_ADDRESS]  
 
Laboratory  asses sments: 
 
Record ANC  
 
Microbiological assessments:  
 
If clinical ly indicated, collect blood sample for culture  (per Section [IP_ADDRESS] ) 
 
If clinical ly indicated , collec t other sample s for cultur e (per Section [IP_ADDRESS] ) 
 
 
[IP_ADDRESS]  Late Follow -Up 
 
Conduct LFU assessments any  time between Study  Days 35 and 42 (ie, 35 to 42 da ys after the 
start of inpatient  IV study drug). The LFU may  be conducted by  [CONTACT_204113] d clinica l failure  since  TOC , did not have ongoing study drug related AEs or 
SAEs at TOC, or did not develop study drug related AEs or SAEs since  TOC . If symptoms 
consistent with clinical failure  or new study drug related AEs or SAE s are noted , or at the 
discretio n of the Investigator , the patien t should b e immediately  scheduled for an in -person visit.  
Also, telephone visit is acceptable for patients who cannot present for a clinic visit.  
 
If LFU  is conducted  by [CONTACT_756]:  
 
Recor d new concomitant medications  
 
Review and record AEs and SAEs  
 
Record Infection Symptoms, Including Recurring or Worsening Symptoms  
 
 2020 -0074  
 06/20/2022  
54  
 Indicative of Clinical Failure  
 
Note: If symptoms consisten t with clinica l failur e or new AEs or SAEs are  noted during the 
telephone interview, or at the  discretio n of the investigator , the subject should be immediately 
scheduled for an i n-person visit  
 
Assess clinical outcome per Section  [IP_ADDRESS]  
 
If LFU  is conducted  in person:  
 
If clinical ly indicated , perfor m CXR (eg, portable anteroposterior film) or chest CT for patients 
with respi[INVESTIGATOR_204081] s ymptoms  
 
Perfor m complet e physical examination  
 
Record  vital signs  (blood  pressure  and pulse  rate, respi[INVESTIGATOR_2842], oxygen saturation [if 
applicable], highest daily temperature)  
 
Record new concomitant medications  
 
Review and record AEs and SAEs  
 
Evaluate and Record Infection Signs and Symptoms Per Section [IP_ADDRESS]  
 
Assess cli nical outcom e per Sectio n [IP_ADDRESS]  
 
Microbiological assessment: In patients experiencing clinical failur e after TOC or if  
clinically  indicated, collect samples for culture per Section  [IP_ADDRESS].[ADDRESS_243343] termination.  
 2020 -0074  
 06/20/[ADDRESS_243344] 
access.  Patient ’s data are to be entere d into the system  by [CONTACT_12244] r or designee using their 
assigned user  accoun t. After data entry  into the s ystem  by [CONTACT_12244] r or designee, a 
combination of manual and programmatic edit checks will be used to review the data for 
completeness, logic, and adherence to study  protocol .  
 
After all data have been reviewed  and all iss ues have been resolved, the database will be locked.  
 
All data collected in the context of this study  will be stored and evaluated per regulatory 
requirements and applicable guidance for electronic records. Also, data will be stored and 
evaluat ed in such a  way as to guarantee  patien t confidentiality  in accordance with the legal 
stipulations appl ying to confidentiality  of data. Study  record s (eg, copi[INVESTIGATOR_1495], laboratory  
reports, patient diaries, regulatory  documents, etc) will be retained at t he site, along with 
adequate source documentation, according to FDA and ICH requirements. All study  records 
must be available for., its authorized representatives, and the FDA or other healt h author ities.  
 
 
9.7 STATI STICAL METHODS A ND DETERMINATION OF 
SAMPLE SIZE  
 
Descriptive statistics (number, mean, SD, median, minimum, and maximum) will be provided 
for continuous variables, and frequency  distributions (counts and percentages) will be show n for 
categorica l variables . All summar y statistics  will be presented by [CONTACT_1570] . In addition, 
the the summar y statistics  will be provided for all randomized patients that received any  amount 
of inpatient IV study drug (MITT Analysis Set) and for the subgroup of patients with a pathoge n 
identifie d (mMIT T Analysis Set). Listings of individual patien ts’ data will also be produced.  
 
A comprehensiv e statistical  analysis plan  will be prepared  and finalized  before  database lock and 
analysis of the data.  
 
9.7.1  Analysis Sets  
 
Anal ysis sets are described below and displa yed in Figur e 9.7.1 –1. 
 2020 -0074  
 06/20/2022  
56  
 Figure  9.7.1–1. Analysis  Sets for Study   
Screened  
Underwen t Baselin e Visit 
and receive d PID number  
 
 
 
Inten t-to-Trea t (ITT) 
All randomized  
   
 
Safety  
Receive d any amount of IV study drug 
  
      
 
    Modifie d Inten t-to-Trea t 
(MIT T) 
           Met minima l diseas e criteria  
 
 
 
 
Clinically  Evaluabl e(CE) 
Met all evaluabilit y 
criteria  
 
     
 Microbiologica l Modifie d Inten-tto-Trea t (mMIT T) 
       ≥ 1 qualifyin g baselin e bacteria l pathog e,n irrespectiv e of 
susceptibil ity to study therapi[INVESTIGATOR_204086](ME)  
Met criteria for both mMITT and CE Analysis Sets  
 2020 -0074  
 06/20/2022  
57  
 [IP_ADDRESS]  Screened Analysis Set  
 
The Screene d Anal ysis Set will consist of all  patien ts who unde rgo the  Baseline  Visit and receiv e 
a PID numbe r. 
 
[IP_ADDRESS]  Intent -To-Treat Analysis Set  
 
The Inten t-to-Treat  Anal ysis Set will consist of all patient s in the Screene d Anal ysis Set who are 
randomized to a treatment group in the stud y. 
 
[IP_ADDRESS]  Safety Analysis Set  
 
The Safety Analysis  Set will be a subset  of the ITT Analysis  Set and will include  all randomized  
patien ts who receiv e any amoun t of inpatient IV study drug. Patients will be analyzed according 
to the treatment actual ly received.  
 
[IP_ADDRESS]  Modified Intent -To-Treat Analysis Set  
 
The MITT Anal ysis Set will be a subset of the ITT Anal ysis Set and will include all randomized  
patien ts who receive d any amoun t of inpatient IV study drug and meet minimal disease criteria 
(Inclusion Criterion 3 ). Patients will be anal yzed according to randomized  treatment  group,  
regardless  of treatment  received.  
 
 
[IP_ADDRESS]  Microbiological Modified Intent -To-Treat Analysis 
Set 
 
The mMIT T Analysis Set will be a subset of the M ITT Ana lysis Set and will include those 
patien ts for whom at least 1 qualif ying bacteria l pathoge n was isolate d from an appropriate 
microbiological specimen at baseline, irrespective of susceptibility  to study  therapi [INVESTIGATOR_014]. 
 
[IP_ADDRESS]  Clinically Evaluable Analysis Set  
 
The CE Analysis Set will be a subset  of the MITT  Anal ysis Set and will include patients who 
meet the following specific conditions for evaluabilit y: 
 
Received at least 80% of the intended doses of  inpatient  IV study drug 
 
Received at least [ADDRESS_243345] 48 hours of IV gram negative antimicrobial coverage to 
be considere d an evaluabl e clinica l cure 
 
Did not receiv e any amoun t of inpatient IV study drug  from the treatment arm to whic h the 
patien t was not randomly  assigned  
 
Had clinical outcome assessment at TOC (othe r than indeterminate ) or was assessed a s a clinical  
failure  at EOIV (or at any  time up to TOC)  
 
Did not receive > 36 hours of a ny potential ly effective, systemic antibacterial thera py within 72 
hours before randomization for treatment of suspected infectio n. Any amount of prop hylactic (in 
 2020 -0074  
 06/20/2022  
58  
 the absence of an infection) antimicrobial (eg, antibacterial, antifungal, antiviral) thera py 
administered prior to starting study  therapy is allowed.  
 
[IP_ADDRESS]  Microbiologic ally Evaluable Analysis Set  
 
The ME Analysis Set will include patien ts who meet  the criteria  for both the CE and mMITT 
analysis sets.  
 
9.7.2  Patient Disposition  
 
Patient disposition (enrollment, discontinuations from inpatient IV study drug, oral or IV 
thera py, and the study) by [CONTACT_204114]. The 
number of patients with a TOC and/or LFU visit will be summarized. Reasons for exclusion 
from study  analysis sets will be summarize d for the ITT Anal ysis Set. 
 
The numbe r of patients in the Safety and ITT analysis sets will be summarized by [CONTACT_22058] t 
group. 
 
Screen failures (ie, patients screened but not randomized) and the associated reasons for failure 
will be tabulated overall.  
 
The numbe r and percentag e of patien ts who complete the treatment period and  of patien ts who 
prematurely  discontinue during the same period  will be presented  for each treatment group and 
poole d acros s treatmen t group s for the  ITT Analysis Set. The reasons for premature  
discontinuation  from  the treatment  period  as recorded  on the termination pag es of the eCRF  will 
be summarized (number and percentage) by  [CONTACT_204115]. 
 
9.7.3  Demographics and Other Baseline Characteristics  
 
Demographics  (eg, age, race, gender , body  mass inde x), medical and surgical histor y, description 
of the infection, markers of disease severity  and co -morbi dities (eg, presence of bacteremia, renal 
impairment), t ype of malignanc y, baseline assessment of the clinical signs and symptoms, and 
microbiological assessment of the primary  infection site will be summarized by  [CONTACT_22058] t group 
in the MITT Analysi s Set. 
 
Prior medication is defined as a ny medication taken before the date of the first dose of 
investigational product. Concomitant medication is defined as a ny medication started on or after 
the date of the first dose of investigational product. A ny prior medications stopped more than [ADDRESS_243346] e administration s of the same medication to a patient will be c ounted 
only once for the given patien t. Medication -related summaries will be presented separately  by 
“systemic antimicrobial medications ” and “other medications not in this clas s” subgroups.  
 
 2020 -0074  
 06/20/2022  
59  
  
9.7.4  Extent of Exposure and Treatment Compliance  
 
 
[IP_ADDRESS]  Extent o f Exposure  
 
Exposure to inpatient  IV study  drug, oral and IV switch  therapy  will be summarized by 
[CONTACT_22058] t group for the Safety Analysis Set. Calendar da ys of exposure of  inpatient IV only, 
oral or IV switch  only, and overall (inpatient  IV plus oral or IV switc h) will be calculated as 
the number of calendar da ys on inpatient  IV study drug/oral or IV switch thera py (ie the 
difference between the last dose of specifie d inpatient  IV study drug/oral or IV switch thera py 
and the first dose of specified inpatient IV study drug/oral or IV switch therapy  date and time 
converted to days + 1 da y). For each type of exposur e both descriptive statistics (number of 
patients, mean, SD, median, minimum, and maximum) and a frequency  tabul ation of da ys of 
specified study  drug treatment by  [CONTACT_204116] < 3 da ys, 3-5 days, 6-8 days, 9-14 days, and > 14 
days and oral therapy  by [CONTACT_204116] < 3, 3, 4, 5 and  > 5 days will be presented.  
 
The numbe r and percentag e of patien ts who switch to oral or IV therapy  will be presented. 
Among this subset of patien ts, the numbe r and percentag e of patients  receiving eac h specifi c 
protoco l-approved  oral or IV therapy  will be summarized. Descriptive statistics  will be provided  
for either  the study day of switch to oral or  IV therap y, as well  as calendar da ys of oral or IV 
therapy (calculated as the date of last dose of the  oral or IV therapy  – date of the first dose of the 
oral or IV therapy  + 1 day). 
 
 
Measurement of Treatment Compliance  
 
Each patien t’s compliance with study  therapy  (inpatient  IV or oral or IV switc h) will be 
calculate d based on the numbe r of doses of study drug the patien t woul d have been expected to 
receive based on the number of treatment da ys, the specific  dosing  regimen indicated for the 
given treatment, and the start and stop date and times of the first and last dose of each specific 
study  therap y. Treatment  compliance  is defined  as the number  of doses actual ly receive d divide d 
by [CONTACT_182610] r of doses expecte d (× 100) over the time period of first dosing date and time to last 
dosing date and time.  
 
Thre e types of study  therapy  compliance will be calculated: IV stu dy therapy  compliance, all 
study  therapi[INVESTIGATOR_014] (both  IV and oral)  compliance,  and, in the subgroup  of patients  who switch to 
oral or IV therap y, oral or IV therapy  compliance. For each compliance measur e, descriptive 
statistics (number of  patien ts, mean, S D, minimum , median , and maximum value) and the 
number and percentage of  patien ts whos e compliance is <  80% versu s ≥ 80% will be presented 
by [CONTACT_204117]. 
 2020 -0074  
 06/20/2022  
60  
 9.7.5  Efficacy Analyses   
The primary efficacy analysis will be based on the MITT analysis set at EOIV. The secondary 
efficacy analyses will be based on MITT, mMITT CE, and ME analysis sets at different time 
points (EOIV, TOC, and LFU). The clinical outcomes definitions with their time points are 
described on section [IP_ADDRESS]. The baseline time point for the efficacy analyses is defined as the 
last measurement collected just before the first dose of inpatient IV study drug.  
The goal of the primary objective of the study is to show t hat the efficacy of Imipenem -
Cilastatin -Relebactam  plus/minus vancomycin, daptomycin or linezolid is non -inferior to the 
standard of care (SOC) plus/minus vancomycin, daptomycin or linezolid as empi[INVESTIGATOR_204087].   
 
 
The non -inferiority margin of efficacy is 10%. The rate of favorable clinical response will be 
estimated for each arm and the rate difference (treatment arm – control arm) and its two -sided 
95% confidence interva l will be calculated. Non -inferiority of Imipenem -Cilastatin -Relebactam  
to the SOC will be declared if the lower confidence interval limit is greater than -10%.  
 
For each secondary efficacy parameter listed below  (Sections: [IP_ADDRESS] and [IP_ADDRESS]) , a 2-sided   chi 
square tests or Fisher’s exact tests will be used to compare the two treatments. When appropriate, 
logistic model will be used to assess the relationship between the efficacy parameter and treatment, 
while adjusting for other factors.  
 
[IP_ADDRESS]  Primary Effic acy Parameter  
The primary  efficacy  parameter is the proportion of patients in the MITT Anal ysis Set with 
favorab le clinical response  at EOIV in accordance with Section [IP_ADDRESS]  
 
[IP_ADDRESS]  Secondary Efficacy Parameters  
 
• The proportion of patients in the  mMITT and CE analysis sets with favorabl e clinical 
respons e at EOIV  
 
• The proportio n of patients in the M ITT Ana lysis Set with favorable  clinical  response at 
TOC and LFU  
 
• The proportion of patients in the mM ITT and CE analysis sets with favorabl e clinical 
respons e by [CONTACT_204100] -negative pathogen at E OIV, TOC, and LFU  
 
• The proportio n of patients in the mM ITT and ME analysis sets with a favorable 
microbiological response by  [CONTACT_204100] -negativ e pathoge n at EOIV, TOC , and LF U. 
A favorabl e microbiological response is defined as eradication or presumed eradicatio n of 
the infectin g pathoge n among patients with microbiologically documen t infections  
 
• The proportion of patients in the M ITT and mMITT ana lysis sets with infecti on-related 
mortality  at TOC and LFU  
 
• The proportion of patients in the M ITT and mMITT analysis sets with 30 -day all-cause 
mortality   
 2020 -0074  
 06/20/2022  
61  
  
[IP_ADDRESS]  Clinical Outcome Definitions   
The definition s of Investigato r-determined  clinical outcome, by  [CONTACT_7206],  are show n in 
Table [IP_ADDRESS] –1. 
 
Successful antimicrobial stewardship (AS) outcome is considered to occur if ≥ 50% of the 
patients enrolled achieve clinical cure at TOC (as per table [IP_ADDRESS] -1) with switch of the study 
drug or SOC to oral or  simplified streamline IV therapy by 72 hours.  
 
Table  9.7.5. 3–1. Clinical  Outcome  Definitions  
 
Applicable  Time  
Point   
Outcome   
Definition  
 
 
EOIV   
 
Favorable  clinical  
response  Resolution of all acute signs and symptoms of the primary infection 
(primarily fever) or improvement to such an extent that no additional 
antibacterial therapy is required (ie, except for protocol -allowed 
adjunctive therapi[INVESTIGATOR_13265]/or oral or IV switch) and such that no more 
than 14 days of total IV antibacterial therapy is required unless 
indicated for a complicated infection.  
 
TOCa  
Clinical  cureb Sustained  resolution  of all acute  signs  and symptoms  of the primary  
infection  or continued  improve ment to such an extent  that no further  IV 
antibacterial  therapy  is required  for the original epi[INVESTIGATOR_1865] . Another 
epi[INVESTIGATOR_204088] -up period will not be 
considered to be a failure unless the patient present for a relapse of 
the same documented infection that was present at baseline.  
 
 
LFUa  
 
Clinical  cureb Sustained  resolution  of all acute  signs  and symptoms  (or of symptoms  
only if LFU  visit is conducted  by [CONTACT_199097]) of the primary  infection  
or continued  improvement  to such  an extent  that no further  IV 
antibacterial  therapy  is required  for the original epi[INVESTIGATOR_1865] . Another 
epi[INVESTIGATOR_204088] -up period will not be 
considered to be a failure unless the patient present for a relapse of 
the same documented infection that was present at baseline.  
 2020 -0074  
 06/20/2022  
62  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EOIVa 
TOCa 
LFUa  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical  failure  Patien ts who meet  any of the follo wing: 
• Has persistent  fever  (ie, a single  oral temperature  measurem ent of 
> 38.0°C  [100.4°F])  96 hours  after the initiation  of study  drug. 
(NOTE:  if the febrile  neutropenia  is documented  to be caused  by 
[CONTACT_204118],  
the patient  should  be considered  to have  an indeterminate  
outcome  for all  clinical  outcome  assessments)  
• Has documented  breakthrough  gram negative bacteremia  (ie, 
recurrence  of bacteremia  that resolved  or occurrence  of new 
bacteremia with gram negative organisms  not present  at 
baseline  while the patient is receiving IV study drug ) 
• Has a documented  pathogen  that is resistant  to any study  therapy  
received  and requires  alternative  nonstudy  antimicrobial  therapy  
• Discontinuation  of study  therapy(ies)  due to insufficient  
therapeutic  effect  including  persistence,  incomplete  clinical  
resolution,  or worsening  in signs  and symptoms  of primary 
documented infection  that requires  alternative  nonstudy  
antimicrobial   
therapy  (Investigator  is encouraged  to continue  study  
therapy[ies]  for at least 48 hours  before  such a patient  is 
considered  a clinical  failure  and is prematurely  discontinued  from  
study  therapy[ies].)  
• Developed  shock,  acute  respi[INVESTIGATOR_57576],  
disseminated  intravascular  coagulation,  or multiorgan  failure  
related  to the primary  infection  
• Discontinuation  of study  drug therapy(ies)  due to an AE and 
requirement  for alternative  nonstudy  antimicrobial  therapy  for 
the primary  infection  
 2020 -0074  
 06/20/2022  
63  
 Table  9.7.5. 3–1. Clinical  Outcome  Definitions  
 
Applicable  Time  
Point   
Outcome   
Definition  
  • Died  as a result  of the primary infection  
 
 
 
 
 
 
 
 
 
EOIVa 
TOCa 
LFUa  
 
 
 
 
 
 
 
 
Indeterminate  • Patients  who developed a documented  invasive  fungal  infection  or 
a documented  viral infection  at any time during  the study  (Note:  
the documented  fungal  or viral infection  must  be the cause  of the 
study  qualifying  epi[INVESTIGATOR_204089])  
• Study  data are not available  for evaluation  of efficacy  for any 
reason,  including:  
o Death  in which  febrile  neutropenia  is clearly  
noncontributory  
o Lost to follo w-up 
o Extenuating  circumstances  precluding  classification  as a 
clinical  cure or clinical  failure  
• Subjects  withdrawn  from  the study  not assessed  as a clinical  
failure  should  be assessed  as indeterminate  at all subsequent  
outcome  evaluation  time points  as noted  in Section  [IP_ADDRESS]  
a A clinical failure at EOIV will be carried forward to TOC. A clinical failure at TOC will be carried forward 
to LFU. TOC  evaluations  include  events  between  EOIV  and TOC (including  events  through  the end of 
oral or IV switch therapy, if applica ble). LFU evaluations include events between TOC and LFU.  No 
scheduled assessment is performed at end of oral or IV switc h therap y. 
b Favorabl e outcom e at TOC or LF U. 
AE = adverse event; EOIV =  End of Inpatient Intravenou s Therapy ; LFU = Late Follo w-up; TOC = Test-of-
Cure.  
 
Perform EOIV assessments within [ADDRESS_243347] dose of inpatient IV study drug  (Day 1 -14).  
Perform TOC assessments between Study Days 21 and 28.  
Perform LFU assessments between Study Days 35 and 42.  
 
 
[IP_ADDRESS]  Microbiological Response Definitions  
 
The timing  and definitions  of per-pathogen microbiological response are shown in  
Table [IP_ADDRESS] –1. Per-patient microbiological response will be determined programmatical ly 
based  on individual  outcomes  for each baseline  pathogen.  For a patient to have a favorable 
microbiological response, the outcome for each baseline pathogen must be favorable (eradicated 
or presumed eradicated). If the outcome for any  pathogen is unfavorabl e (persistenc e or 
presume d persistence) , the patient will be considered to have an unfavorabl e microbiologica l 
response.  
 
 
 2020 -0074  
 06/20/2022  
64  
 Table  9.7.5. 4–1. Microbiological  Response  Definitions  
 
Applicable  
Time  Point   
Microbiological  Response   
Definition  
EOIV  
TOC  
LFU   
Eradicatio na  
Source  specimen  demonstrates  absence  of the original  
baseline  pathogen  
EOIV  
TOC  
LFU   
Presumed  eradicatio na  
Source  specimen  was not available  to culture  and the 
patient  was assessed  as a clinical  cure 
EOIV  
TOC  
LFU   
Persistence   
Source  specimen  demonstrates  continued  presence  of 
the original  baseline  pathogen  
EOIV  
TOC  
LFU   
Presumed  persistence   
Source  specimen  was not available  to culture  and the 
patient  was assessed as a clinical  failure  
EOIV  
TOC  
LFU   
Indeterminate  Source  specimen  was not available  to culture  and the 
patien t’s clinical  response  was assessed  as 
indeterminate  
a Favorable outcom e. 
EOIV  = End of Inpatient  Intravenous  Therapy ; LFU = Late Follo w-up; TOC = Test-of-Cure. 
 
[IP_ADDRESS]  Emergent Infections  
 
Organisms  or pathogens  first appearing  after baseline  (emergent  infections)  are defined  in 
 
Table [IP_ADDRESS] –1 and will be summarized separatel y. 
 
 
 
Table  9.7.5. 5–1. Emergent  Infections  
 
Infection  Category  Definition  
 
Colonization  Isolation  of a new organism(s)  different  than any isolated  at baseline  from  the site 
of infection  in a patient  who is assessed  as a clinical  cure 
 
Superinfection  Isolation  of a new pathogen(s)  different  than any isolated  at baseline  from  the site 
of infection  during  treatment  with study  drug therap y, which  is associated  with 
emergence  or worsening  of signs  and symptoms  of infecti on 
 
New  infection  Isolation  of a new pathogen(s)  different  than any isolated  at baseline  from  the site 
of infection  after completion  of all study  drug therapy,  which  is associated  with 
emergence  or worsening  of signs  and symptoms  of infection  
 
 
Safety Analyses   
For the primary safety  and tolerability objective , the incidenc e of TEAE s, SAEs, deaths, and 
discontinuations due to AEs will be summarized by  [CONTACT_22058] t group , system organ class and 
preferred term according to the Medical Dictionary for Regulatory Activitie s, type, frequency, 
relationship to study  therap y, and severi ty. Safety  summaries will be presented using the Safety  
 2020 -0074  
 06/20/[ADDRESS_243348] dose of inpatient  IV study drug will be used as the baselin e for 
all analyses.  Descrip tive statistics of observed results and the change from baseline will be 
presented for clinical laboratory  results and vital signs. The incidence of potentially  clinically 
significan t (PCS)  laboratory  results will be summarized.  A list of all TEAEs/SAEs t hat resulted  
in deaths  will also be generated.  The c hanges in clinical laboratory  parameters and vital sign 
parameters in the Safe ty Anal ysis Set at each study  visit that assessment s will be  performed .  
 
. 
 
 
 
[IP_ADDRESS]  Adverse Events  
 
An AE (classifie d by [CONTACT_204119] d term) that occu rs during the treatment period will be considere d a 
TEA E if it was not presen t before  the date of the first dose of investigational produc t or was 
presen t before  the date of the  first dose of investigational product and increase d in severi ty 
durin g the treatmen t period . If more than [ADDRESS_243349]  will not be counted  as a TEAE.  
 
The numbe r and percentag e of patien ts reporting TEAEs in each treatment group will be 
tabulate d by [CONTACT_6657]; by  [CONTACT_2943],  preferred term, and 
severit y; and by  [CONTACT_9313], preferred term, and  causa l relationship to the investigationa l 
product . If more than [ADDRESS_243350] . 
 
The distribution of TEAEs by  [CONTACT_204120] t will 
be summarized by  [CONTACT_1570].  
 
The incidence of common (eg, ≥ 2% of patients in any  treatment group) TEAEs,  on-thera py 
SAEs, and AEs leading to premature discontinuation of  the investigational produc t will be 
summarized by  [CONTACT_204121] t. In addition,  the incidenc e of fatal on -thera py SAEs (ie, events  that caused  
death)  will be summarized  separate ly by [CONTACT_22058] t group an d preferre d term. An SAE will be 
defined as an on -thera py SAE if it occurre d on or afte r the date of the first dose of doubl e-blind 
investigational  product  and within [ADDRESS_243351].  
 
Listings will be presented for patients with SAEs, patients with AEs leading to discontinuation, 
and patients who die (if a ny). 
 
 
 [IP_ADDRESS]  Clinical Laboratory Parameters  
 
Descriptive statistics for clinical laboratory  values  (in SI units) and changes from the baselin e 
 2020 -0074  
 06/20/[ADDRESS_243352] PCS laboratory  values will also be provided.  
 
 
 [IP_ADDRESS]  Vital Signs  
 
Descriptiv e statis tics for vital signs (ie, systolic and diastolic blood pressur e, pulse rate, 
respi[INVESTIGATOR_2842], oxygen saturation [if applicable], temperatur e) and changes from b aselin e value s 
at each visit and at end of study  will be presented by [CONTACT_22058] t group.  
 
Vital s ign value s will be  PCS if they  meet  both the observe d-value  criteria  and the change from 
baselin e–value  criteria  detaile d in the statistica l analysis plan. The percentages will be calculate d 
relativ e to the numbe r of patients with b aselin e value s and at least one postb aselin e assessmen t. 
The numerato r will be the total numbe r of patien ts with availabl e baseline values and  at least one 
PCS postb aselin e value. A supportive listing of patien ts with PCS postb aselin e values will be 
provided, includin g the PID number, and baseline  and postbaselin e values. A  listin g of all AEs 
that occur in patien ts who have PCS vital sign value s will also be provided.  
 
 [IP_ADDRESS]  Chest Radiography  
 
Readings  of the baseline  chest  radiographs  including  the presence  of pleural  effusion, whether  
the pleural  effusion  was unilateral  or bilatera l, and whether the pulmonary infiltrat e was uni- or 
multi -lobar and/o r cavitate d will be summarized by  [CONTACT_204122]. 
 
 
 
 [IP_ADDRESS]  Toxicity Stoppi[INVESTIGATOR_204090] 2 (BOP2) design (Zhou, Lee and Yuan, 
2017)34. Toxicities used for this monitoring rule consist of severe (Grade ≥3) drug related 
adverse events leading  to the discontinuation of the study  drug. Toxicity monitoring will be 
carried out independently for the two arms,  in cohort size of 10. Specifically, let 𝑛 denote the 
interim sample size and 𝑁 denote the maximum sample size. Let 𝑝𝑡𝑜𝑥 denote the pro bability of 
toxicity and define the null hypothesis 𝐻0:𝑝𝑡𝑜𝑥>0.35, under which the treatment is deemed 
as unacceptable. Thus, we will stop enrolling patients and inspect the safety data for possible 
trial termination if  
 2020 -0074  
 06/20/2022  
67  
 𝑃𝑟(𝑝𝑡𝑜𝑥≤0.35|𝑑𝑎𝑡𝑎)<𝜆(𝑛
𝑁)𝛼
, 
where 𝜆=0.86 and 𝛼=0.62 are design parameters optimized to maximize the probability of 
correctly concluding that a safe treatment is acceptable under the alternative hypothesis 
𝐻1:𝑝𝑡𝑜𝑥=0.2, while controlling the type I error rate  (i.e., the probability of incorrectly 
concluding that an overly toxic treatment is acceptable) at 0.1. This optimization is performed 
assuming a vague prior Beta(0.35,0.65) for 𝑝𝑡𝑜𝑥. The above decision rule leads to the following 
optimal stoppi[INVESTIGATOR_204091]:  
Table [IP_ADDRESS]–1.  Optimized stoppi[INVESTIGATOR_74239]  
# patients treated  Stop if # toxicity >=  
10 5 
20 8 
30 10 
40 13 
50 14 
 
Based on Table [IP_ADDRESS] –1, we perform the interim analysis when the number of enrolled patients 
reaches 10, 20, 30, 40. When the total number of patients reaches the maximum sample size of 
50, we reject the null hypothesis and conclude that the treatment is acceptable if the number  of 
toxicities are less than 14; otherwise we conclude that the treatment is unacceptable.  
 
Below are the operating characteristics of the design using the BOP2 web application, which is 
available at http://www.tr ialdesign.org . 
Table [IP_ADDRESS] –2.   Operating characteristics  
Toxicity rate  Early stoppi[INVESTIGATOR_007] (%)  Claim acceptable (%)  Sample size  
0.1 0.22  99.76  49.9  
0.2 9.75  85.12  47.3  
0.3 52.57  29.36  36.0  
0.4 90.64  2.40  22.6  
0.5 99.44  0.04  15.2  
The Investigator is responsible for completing an efficacy/safety summary report and submitting 
it to the IND office Medical Affairs and Safety Group, for review and approval.   
 
This should be submitted after the first [ADDRESS_243353] ete in -patient 
intravenous therapy, and every 10 evaluable patients per arm, thereafter.  
 
A copy of the cohort summary should be placed in the Investigator’s Regulatory Binder under 
“funder correspondence”.  
 
 
 2020 -0074  
 06/20/2022  
68  
 [IP_ADDRESS] Pregnancy Related Risk   
Birth Control Specifications: If you can become pregnant or father a child, you must use 2 forms of 
birth control. Acceptable forms of birth control include either 2 barrier methods (like a condom or 
diaphragm with spermicide) or 1 barrier method plus a hormonal method (such as birth control 
pi[INVESTIGATOR_3353]/injections/patches).  
 
Males: Tell the doctor right away if your partner becomes pregnant or suspects pregnancy while on 
study or within [ADDRESS_243354] dose of study drugs. If your partner/spouse becomes pregnant 
while you are on this study, the sponsor would like to collect information about the pregnancy. The 
study sponsor's contact [CONTACT_204123], if you and your partner wish to, 
you can share information about the outcome of  the pregnancy with the sponsor. If you and/or your 
partner choose not to share this information, it will not result in any penalty or loss of benefits to 
which you are otherwise entitled.  
 
 
9.7.7  Antimicrobial Stewardship and Outcomes Research 
Analyses   
Successful antimicrobial stewardship (AS) outcome is considered to occur if ≥ 50% of the 
patients enrolled achieve clinical cure at TOC (as per table [IP_ADDRESS] -1) with switch of the study 
drug or SOC to oral or simplified streamline IV therapy by 72 hours.  
 
9.7.8  Interim Analysis  
 
No futility interi m analysis is planned for this stud y as Imipenem -Cilastatin -Relebactam  has FDA 
approval for the treatment of HABP/VABP, and also approved for cUTI and cIAI, and Imipenem 
has over 35 years of clinical use and prove n efficacy . Safety interim analysis is provided in 
Section [IP_ADDRESS] . 
 
 
9.7.9  Determination of Sample Size  
 
The primary objective of the study is determine the  efficac y of Imipenem -Cilastatin -Relebactam  
plus/minus  vancomycin, daptomycin or linezolid is non -inferior to the standar d of care (SOC) 
plus/minus  vancomycin, daptomycin or linezolid  as empi[INVESTIGATOR_204092].  The historical favorable clinical response 
for the SOC is approximately 65%. We expect that the favorable clinical response of Imipenem -
Cilastatin -Relebactam  plus/minus  vancomycin, daptomycin or linezoli d is 80%. Given the non -
inferiority margin of 10% (i.e., if the favorable clinical response of Imipenem -Cilastatin -
Relebactam  is >55% , it is deemed non -inferior to the SOC), the sample size of [ADDRESS_243355] 80% power to establish the non -inferiority. This power calculation was performed 
using East with null response rate of 0.55, alternative response rate of 0.8, one -sided chi -squared 
test at significance level of 0.05.  
 
 
 
9.7.10  Computer Methods  
 
Statistical anal yses will be  performed  using  SAS v ersio n 9.3. 
 2020 -0074  
 06/20/[ADDRESS_243356] OF THE STUDY OR 
PLANNED ANALYSES  
 
No protocol amendment may  be implemented (with the exceptions noted below) before it has 
been approved by  [CONTACT_1201]. If the pro tocol is amended to eliminate or reduce the r isk to  patien ts, 
the amendment may  be implemente d befor e IRB revie w and approva l. However , the IRB must be 
informed in writin g of such an amendment , and approva l must be obtained within reasonable 
time limits.  
 
 
9.9 PROTOCOL DEVIATIONS  
 
A protocol deviation  is any  change, divergence, or departure from the study  design or procedures 
that is under the  Investigator’ s responsibility  and oversight (as defined by [CONTACT_19124] ) withou t 
prior writte n IRB approva l or favorabl e opi[INVESTIGATOR_3078] n of an appropriate amendment  and that does not 
have  a major  impact  on the patien t’s rights, safet y, or well-being , or on the integri ty and 
authenticit y of the study data. Deviation s may include, but are not limited  to, departure  from  
inclusion/exclu sion criteria , allowed concomitant medications , dosing  or duration of treatment, 
failure  to follow withdrawa l criteri a or perform the required assessments at specified time points, 
and scheduling of visits not in accordance with specificatio ns. 
 
Deviatin g from the protocol is permitted only  if absolutely  necessary  for the safe ty or clinica l 
managemen t of the patien ts.   
 
The IRB must be notified accordin g to the criteri a and time period dictated by  [CONTACT_204124] y. 
 
 
10.0 STUDY  FUNDER SHIP  
 
MD Anderson  Cancer Center IND office (Study Funder ); [COMPANY_006], Inc. (Supporting Company)   
 
10.[ADDRESS_243357] maintain the following during the stud y: 
 2020 -0074  
 06/20/[ADDRESS_243358] operating procedures at MD Anderson . It is the Investigato r’s 
responsibility  to ensure that  patien ts return their investigationa l product . 
 
 
11.[ADDRESS_243359] of this stud y, including case report forms , 
source documents, consent forms, regulatory  documents, clinical laboratory result s, calibratio n 
logs, or reports (including, but not limited to, all local and central laboratory  results and 
electrocardiogra m reports), and medication inventory  records in all formats (including, but not 
limited to, written, electronic, magnetic, and optical records, and scans , x-rays, and 
electrocardiograms) must be retained by  [CONTACT_12244] r according to  institutional policies .  
 
The Investigato r must permit access to any  documentation relating to the study  upon request of 
the Funder  or applicable regulatory  authorities. If the  Investigator  for the study  retires, relocates, 
or for other reasons withdraws from the responsibility  of keepi[INVESTIGATOR_13274], custody  must 
be transferred to a suitable alternate custodian emplo yee of the institution or to a suitably  
qualified and responsible third part y.  
 
11.5 PATIEN T CONFIDENTIALITY  
 
All patient records will only be identified by [CONTACT_204125].  
 
 
12.0 APPENDICES  
 
APPENDI X I. ELEMENTS OF INFORMED  CONSENT  
 2020 -0074  
 06/20/2022  
71  
  
Procedures will comply  with 21 CFR, Parts 50 and 312. Signed informed consent will be 
obtaine d from each patient participatin g in a clinica l researc h study  or from the patien t’s legally  
authorized repres entativ e. This consent must include the following items:  
 
• A statement  that the study  involves  research  and an explanation  of the purposes  of the research;  a 
description  of the procedures  to be followed  and the identification of any procedures that are 
experimental;  and the expected  duration  of the patien t’s participation  
 
• A descriptio n of any reasonably  foreseeable risks or discomforts to the patient  
 
• A descriptio n of any benefit s to the patien t or to others that may  reasonably  be expected from the 
researc h. If the patient is to be paid for participating in the stud y, the consen t form must state the 
amoun t that he/she will receive and the schedule of pa yment (to ensure neither coercion nor 
undue influen ce) 
 
• A disclosure  of appropriate  alternative  procedures  or courses of treatment, if an y, that might be 
advantageous to the  patient  
 
• A statement describing the extent, if an y, to which confidentiality  of records identif ying the 
patien t will be maintained and noting the possibility  that the FD A; [COMPANY_006] , Inc.; the IRB; or an 
authorized contract research organization may  inspect the records  
 
• For research involving more than minimal risk, an explanation of whether any medical treatment 
is available i f injury  occurs and, if so, what it consists of or where further information may  be 
obtained  
 
• An explanatio n of whom to contact , includin g the relevan t telephone number, for answers to 
pertinent questions about the research and  the researc h patient ’s rights and who m to contac t in 
the event of a research -related  injury  to the patien t. (Note: In some cases, it may be necessary  to 
identify  a perso n other than the Investigato r as the contac t. The guidance of the IRB may be 
required)  
 
• A statement that participation is voluntar y, that refusal to participate will involve  no penalty  or 
loss of benefits to which the patien t is otherwise entitled, and that the patien t may discontinue 
participation at any  time without penalty  or loss of benefit s to whic h the patien t is otherwise 
entitled .
 2020 -0074  
 06/20/2022  
72  
 • A statement  that the particular  treatment or procedures may  involve risks to the patien t (or to the 
embr yo or fetus if the patien t is, or may  become, pregnant) that are at presen t unforeseeable  
 
• The expected circumstances for whic h the patien t’s participation may  be terminated by [CONTACT_204126]’s consent  
 
• Any additional costs to the patien t that  may result from participation in the research  
 
• The consequence s of a patient’s decision to withdraw from the research and procedure s for an 
order ly terminatio n of the patie nt’s participation  
 
• A statemen t that significan t new finding s develope d durin g the cours e of the research that may  
relate to the  patient’s willingness to  continue participation will be provided to the patient  
 
• The approximate number of  patien ts involved in the study  
 
• A statement  of consent  (eg, “I agree to participate  . . .”) 
 
• A place for the patien t’s signature [CONTACT_204131]  
 
• A statement indicating that information about this study  has been , or will be, entered into a 
databank that is publicly  accessibl e at www.ClinicalTrials.gov.  
 
• A copy of the signed  consent form must be given to the patien t. All participants will be registered 
in the Clinical Oncology Research System (CORe ). 
 
 
 
 
 
 
 
 
 
 2020 -0074  
 06/20/2022  
73  
 APPENDI X II. MD AND ERSON NEUTROPENIC  FEVER INPATIENT ADUL T TREATMEN T GUID ELINES  

 2020 -0074  
 06/20/2022  
74  
 

 2020 -0074  
 06/20/2022  
75  
 

 2020 -0074  
 06/20/2022  
76  
 

 2020 -0074  
 06/20/2022  
77  
 

 2020 -0074  
 06/20/2022  
78  
 

 2020 -0074  
 06/20/2022  
79  
 

 2020 -0074  
 06/20/2022  
80  
 

 2020 -0074  
 06/20/2022  
81  
  
 
 

 2020 -0074  
 06/20/2022  
82  
  
APPENDI X III. MD AND ERSO N PNEUMON IA IN ADULT PATIENTS WITH CANCE R TREATMEN T 
GUIDELINES  
 
 

 2020 -0074  
 06/20/2022  
83  
 

 2020 -0074  
 06/20/2022  
84  
 

 2020 -0074  
 06/20/2022  
85  
 

 2020 -0074  
 06/20/2022  
86  
 

 2020 -0074  
 06/20/2022  
87  
 

 2020 -0074  
 06/20/2022  
88  
 

 2020 -0074  
 06/20/2022  
89  
 

 2020 -0074  
 06/20/2022  
90  
 

 2020 -0074  
 06/20/2022  
91  
  
 
 

  2020 -0074  
 06/20/2022  
92  
 APPENDI X IV. POTENTIAL DRU G-INDUCED LIVER INJURY/HY’S 
LAW   
IDENTIFICATION   
The Investigato r is responsibl e for determinin g whethe r a patient meets  the following potential 
Hy’s law (PHL) criteri a at any point after initiation of study  therapy  (IV or oral) . For  a PHL case 
to meet H y’s Law, the increases from baseline in AST or ALT  and 
total bilirubin values, in the Investigator’ s clinica l judgment , should  be temporally  related to one 
another and to the administration of study  drug, without an alternative explan ation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  2020 -0074  
 06/20/[ADDRESS_243360] or ALT ≥ 3 × ULN; total bilirubin ≥  2 × ULN and ALP < 2 × ULN  
 
If there are increases from baseline in AST or ALT ≥  3 × ULN  and total bilirubin  ≥ 2 ×  ULN: 
 
• The Investigator must follow the instructions in this appendix  
 
• The investigativ e site must complete the appropriate screen(s) of the eCRF with the local 
laboratory  test results  
 
 
FOLLOW -UP AND  REPORTING   
If the Investigator determines that the  patien t has not met PHL criteria (has not had increase s 
from baselin e in AST or ALT ≥ 3 ×  ULN and total bilirubin ≥ 2  × ULN and ALP < 2 × ULN,  at 
any point after initiation of study  drug), the Investigator is to perform follo w-up on subsequent 
laboratory  results as required for  patien t care and per protocol Section [IP_ADDRESS].2 . 
 
If the Investigato r determines that the patien t has met PHL criteria (has had AST or ALT ≥ 3 × 
ULN and total bilirubin ≥ 2 ×  ULN, and A LP < 2  × ULN , elevate d from baselin e at any point 
after initiation of study  drug):  
 
• The Investigato r shoul d revie w the criteri a for prematur e discontinuation of study drug due to 
elevated liver chemistry  values, per protocol Section  9.3.3  
 
• Any PHL case should be handled as an SAE associated with the use of the drug and reported as 
an SAE per protocol Section  [IP_ADDRESS] (ie, even before all other possible causes of liver injury  have 
been excluded). It should be promptly  reporte d before doin g a full worku p on the patien t to rule 
out other  etiologies  
  2020 -0074  
 06/20/2022  
94  
 • The Investigator will investigate the etiolog y of the event and establish if another 
explanation/alternative  cause other than dru g-induced liver injury  caused  by [CONTACT_204127]. The Funder  may be contact[CONTACT_204128] k-up. 
 
• The investigative site must complete the appropriate screens of the eCRF  
 
If there is an alternative explanation or the liver chemistry  values increased from baseline areno t 
temporally  related to one another and to the initiation of study  drug, the Investigator should 
update the PHL SAE to reflec t the attributed under lying illness and reassign an appropriate 
causality  assessment, per protocol Sections [IP_ADDRESS] and [IP_ADDRESS] , respective ly. 
 
If there  is no alternative  explanation  and the liver chemistry  values  increased  from baselin e are 
temporal ly related to one another and to the initiation of study  drug, the Investigato r shou ld 
update the PHL SAE to a H y’s Law case (reported term ‘H y’s Law’) and reassign a causality  
assessment of “relat ed.” 
 
If, despi[INVESTIGATOR_204093]’s attempts to conduct follo w-up and the guidance provided in this 
appendix, there is an unavoidable delay  of > 3 weeks in obtaining the information necessary  to 
assess whether or not the case meets the criteria for a H y’s case, then it is assumed that there is 
no alternative explanation until such time as an informed decision can be made.  
 
 
REFERENCE   
US Food and Drug Administration. Guidance for Industr y. Drug-induced liver injur y: 
Premarketing clinical evaluation.  2009 Jul. Avai lable from: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/  
Guidances/UCM174090.pdf.  Accessed  [ADDRESS_243361] 28.  
 
 
 
 
 
 2020 -0074  
 06/20/2022  
95  
 Table  II  
 
Trial description  n Treatment regimens  Primary outcomes  Primary outcome 
results  n/N (%)  Secondary outcomes  Secondary outcome results  
n/N (%)  
Phase II treatment of  
cIAI (21) 
ClinicalTrials.gov 
ID: 
[STUDY_ID_REMOVED]  351 Imipenem/relebactam  
500/250 mg IV (t’ 30  min) 
q6 h × 4–14 days 
Imipenem/relebactam  
500/125  mg IV ( t’ 30 min) 
q6 h × 4–14 days 
Imipenem  
500 mg IV ( t’ 30 min) 
q6 h × 4–14 days Clinical responsea in 
the MEbpopulation 
at DCIV  Relebactam 250  mg: 
78/81 (96.3)  
Relebactam 125  mg: 
85/86 (98.8)  
Imipenem alone:  
79/83 (95.2)  Clinical responsea at EFU 
(MEb) Relebactam 250  mg: 75/79 (94.9)  
Relebactam 125  mg: 81/86 (94.2)  
Imipenem alone: 78/81 (96.3)  
Clinical responsea at LFU 
(MEb) Relebactam 250  mg: 74/79 (93.7)  
Relebactam 125  mg: 81/85 (95.3)  
Imipenem alone: 75/79 (94.9)  
Microbiologic responsec at 
DCIV (MEb) Relebactam 250  mg: 81/83 (97.6)  
Relebactam 125  mg: 86/86 (100)  
Imipenem alone: 82/84 (97.6)  
Global responsed at 
28 days 
after randomization 
(MITTe) Relebactam 250  mg: 77/89 (86.5)  
Relebactam 125  mg: 86/96 (89.6)  
Imipenem alone: 78/92 (84.8)  
Phase II treatment of  
cUTI and AP (14) 
ClinicalTrials.gov 
ID: 
NCT0150 5634  302 Imipenem/relebactam  
500/250  mg IV ( t’ 30 min) 
q6 h × 4–14 days 
Imipenem/relebactam  
500/500/125  mg IV ( t’ 30 min) 
q6 h × 4–14 days 
Imipenem  
500/500  mg IV ( t’ 30 min) 
q6 h × 4–14 days 
Optional oral step -down after 
4 days (all regimens): 
ciprofloxaci n 500  mg BID  Microbiological 
responsec in the 
MEbpopulation at 
DCIV  Relebactam 250  mg: 
64/67 (95.5)  
Relebactam 125  mg: 
70/71 (98.6)  
Imipenem alone:  
74/75 (98.7)  Microbiological 
responsec at 
EFU/LFU (MEb) Relebactam 250  mg: (61.5/68.3)  
Relebactam 125 mg: (68.1/65.2)  
Imipenem alone: (70.4/62.5)  
Clinical responsea at 
DCIV/EFU/LFU (MEb) Relebactam 250  mg: 
(97.1/89.1/88.7)  
Relebactam 125  mg: 
(98.7/91.8/87.3)  
Imipenem alone: (98.8/93.4/88.2)  
Microbiological 
responsec at 
DCIV for INS infections 
(MEb) Relebactam 250  mg: 10/10 (100)  
Relebactam 125  mg: 7/7 (100)  
Imipenem alone: 6/6 (100)  
 
  2020 -0074  
 06/20/2022  
96  
 13.0 LITERATURE CITED  
 
 
1. Prevention CfDCa. Antibiotic resistance threats in the [LOCATION_002] 2013 [Available 
from: https://www.cdc.gov/drugresistance/pdf/ar -threats -2013 -508.pdf . 
2. Cerceo E, Deitelzweig SB, Sherman BM, Amin AN. Multidrug -Resistant Gram -Negative 
Bacterial Infections in the Hospi[INVESTIGATOR_204094]: Overview, Implications for Clinical Practice, and 
Emerging Tre atment Options. Microb Drug Resist. 2016;22(5):412 -31. 
3. Patel TS, Nagel JL. Clinical outcomes of Enterobacteriaceae infections stratified by 
[CONTACT_204129]. J Clin Microbiol. 2015;53(1):[ADDRESS_243362] Ther. 2013;11(3):297 -308. 
5. Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the 
association of bacteraemia caused by [CONTACT_89927] -spectrum beta -lactamase -producing 
Enterobacteriac eae and patient outcome: a meta -analysis. J Antimicrob Chemother. 
2012;67(6):1311 -20. 
6. American Thoracic S, Infectious Diseases Society of A. Guidelines for the management 
of adults with hospi[INVESTIGATOR_307] -acquired, ventilator -associated, and healthcare -associated  pneumonia. Am 
J Respir Crit Care Med. 2005;171(4):[ADDRESS_243363] Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 
2013;68(10):[ADDRESS_243364] of antibiotic -resistant bacteria to guide research, 
discovery, and development of new antibiotics 2017 [Available from: 
https://www.who.int/medicines/publications/global -priority -list-antibiotic -resistant -bacteria/en/ . 
9. Rizk ML, Rhee EG, Jumes PA, Gotfried MH, Zhao T, Mangin E, et al. Intrapulmonary 
Pharmacokinetics of Relebactam, a Novel beta -Lactamase Inhibitor, Dos ed in Combination with 
Imipenem -Cilastatin in Healthy Subjects. Antimicrob Agents Chemother. 2018;62(3).  
10. Rizk ML JP, Lasseter K, et al, editor Pharmacokinetics of MK -7655, a novel b -lactamase 
inhibitor (BLI), in combination with imipenem/cilastatin (IP M/CIL) in subjects with impaired 
renal function. 52nd Interscience Conference on  
Antimicrobial Agents and Chemotherapy (ICAAC); 2012; San Francisco, CA.  
11. Centers for Disease C, Prevention. Vital signs: carbapenem -resistant Enterobacteriaceae. 
MMWR Morb Mortal Wkly Rep. 2013;62(9):165 -70. 
12. Jacob JT, Klein E, Laxminarayan R, Beldavs Z, Lynfield R, Kallen AJ, et al. Vital Signs: 
Carbapenem -Resistant Enterobacteriaceae. Mmwr -Morbid Mortal W. 2013;62(9):165 -70. 
13. Tzouvelekis LS, Markogiannakis A, Psichog iou M, Tassios PT, Daikos GL. 
Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of 
global dimensions. Clin Microbiol Rev. 2012;25(4):682 -707. 
14. Sims M, Mariyanovski V, McLeroth P, Akers W, Lee YC, Brown ML, et al. P rospective, 
randomized, double -blind, Phase 2 dose -ranging study comparing efficacy and safety of 
imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated 
urinary tract infections. J Antimicrob Chemother. 2017;72(9):[ADDRESS_243365] -1, a plasmid -mediated AmpC 
beta-lactamase, and the foss of an outer membrane protein. Antimicro b Agents Chemother. 
  2020 -0074  
 06/20/2022  
97  
 1997;41(3):563 -9. 
16. Crowley B, Benedi VJ, Domenech -Sanchez A. Expression of SHV -2 beta -lactamase and 
of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to 
cephalosporins and carbapenems. Antimi crob Agents Chemother. 2002;46(11):[ADDRESS_243366] 
expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob 
Agents Chemother. 2006;50(5):1633 -41. 
18. Zavascki AP, Carvalhaes CG, Pi[INVESTIGATOR_204095], Gales AC. Multidrug -resistant Pseudomonas 
aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. 
Expert Rev Anti Infect Ther. 2010;8(1):71 -93. 
19. Karlowsky JA, Lob SH, Kazmi erczak KM, Hawser SP, Magnet S, Young K, et al. In 
vitro activity of imipenem/relebactam against Gram -negative ESKAPE pathogens isolated in 17 
European countries: 2015 SMART surveillance programme. J Antimicrob Chemother. 
2018;73(7):1872 -9. 
20. Papp -Wallac e KM, Barnes MD, Alsop J, Taracila MA, Bethel CR, Becka SA, et al. 
Relebactam Is a Potent Inhibitor of the KPC -2 beta -Lactamase and Restores Imipenem 
Susceptibility in KPC -Producing Enterobacteriaceae. Antimicrob Agents Chemother. 
2018;62(6).  
21. Lucasti C , Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, et al. Phase 2, 
Dose -Ranging Study of Relebactam with Imipenem -Cilastatin in Subjects with Complicated 
Intra -abdominal Infection. Antimicrob Agents Chemother. 2016;60(10):6234 -43. 
22. Motsch J, Murt a de Oliveira C, Stus V, Koksal I, Lyulko O, Boucher HW, et al. 
RESTORE -IMI 1: A Multicenter, Randomized, Double -blind Trial Comparing Efficacy and 
Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem -
nonsusceptible Bacterial I nfections. Clin Infect Dis. 2020;70(9):1799 -808. 
23. Imipenem/Relebactam/Cilastatin Versus Pi[INVESTIGATOR_049]/Tazobactam for Treatment of 
Participants With Bacterial Pneumonia (MK -7655A -014) (RESTORE -IMI 2).  
24. Wu J, Racine F, Wismer MK, Young K, Carr DM, Xiao JC, et al. Exploring the 
Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK -7655) in Combination 
with Imipenem in a Hollow -Fiber Infection Model. Antimicrob Agents Chemother. 2018;62(5).  
25. Al Shuaibi M, Bahu RR, Chaftari AM, Al Wohoush I, Sho mali W, Jiang Y, et al. Pro -
adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in 
febrile patients with hematologic malignancies. Clinical infectious diseases : an official 
publication of the Infectious Diseases So ciety of America. 2013;56(7):943 -50. 
26. Shomali W, Hachem R, Chaftari AM, Jiang Y, Bahu R, Jabbour J, et al. Can 
procalcitonin distinguish infectious fever from tumor -related fever in non -neutropenic cancer 
patients? Cancer. 2012;118(23):5823 -9. 
27. Shomali W, Hachem R, Chaftari AM, Bahu R, Helou GE, Jiang Y, et al. Can 
procalcitonin differentiate Staphylococcus aureus from coagulase -negative staphylococci in 
clustered gram -positive bacteremia? Diagnostic microbiology and infe ctious disease. 
2013;76(2):158 -61. 
28. Chaftari AM, Hachem R, Reitzel R, Jordan M, Jiang Y, Yousif A, et al. Role of 
Procalcitonin and Interleukin -6 in Predicting Cancer, and Its Progression Independent of 
Infection. PloS one. 2015;10(7):e0130999.  
29. Debi ane L, Hachem RY, Al Wohoush I, Shomali W, Bahu RR, Jiang Y, et al. The utility 
of proadrenomedullin and procalcitonin in comparison to C -reactive protein as predictors of 
  2020 -0074  
 06/20/2022  
98  
 sepsis and bloodstream infections in critically ill patients with cancer*. Crit Care  Med. 
2014;42(12):2500 -7. 
30. El Haddad H, Chaftari AM, Hachem R, Chaftari P, Raad, II. Biomarkers of Sepsis and 
Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin With Emphasis in 
Patients With Cancer. Clinical infectious diseases : a n official publication of the Infectious 
Diseases Society of America. 2018;67(6):971 -7. 
31. Haddad HE, Chaftari AM, Hachem R, Michael M, Jiang Y, Yousif A, et al. Procalcitonin 
Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Document ed Infection 
or Neutropenia. Sci Rep. 2018;8(1):1099.  
32. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy 
and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically 
ill patients:  a randomised, controlled, open -label trial. The Lancet Infectious diseases. 
2016;16(7):819 -27. 
33. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of 
procalcitonin to reduce patients' exposure to antibiotics in intensive care uni ts (PRORATA trial): 
a multicentre randomised controlled trial. Lancet. 2010;375(9713):463 -74. 
34. Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, et al. 
Procalcitonin algorithm in critically ill adults with undifferentiated infectio n or suspected sepsis. 
A randomized controlled trial. Am J Respir Crit Care Med. 2014;190(10):[ADDRESS_243367] FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. 
Intensive care medicine. 1998;24(8):888 -9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 